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The sickle hemoglobin is an abnormal hemoglobin due to point mutation (GAG → GTG) in exon 1 of the β globin gene resulting
in the substitution of glutamic acid by valine at position 6 of the β globin polypeptide chain. Although the molecular lesion is a
single-point mutation, the sickle gene is pleiotropic in nature causing multiple phenotypic expressions that constitute the various
complications of sickle cell disease in general and sickle cell anemia in particular. The disease itself is chronic in nature but many
of its complications are acute such as the recurrent acute painful crises (its hallmark), acute chest syndrome, and priapism. These
complications vary considerably among patients, in the same patient with time, among countries and with age and sex. To date,
there is no well-established consensus among providers on the management of the complications of sickle cell disease due in part
to lack of evidence and in part to diﬀerences in the experience of providers. It is the aim of this paper to review available current
approaches to manage the major complications of sickle cell disease. We hope that this will establish another preliminary forum
among providers that may eventually lead the way to better outcomes.
1. Introduction
Sickle cell disease (SCD) is an inherited chronic hemato-
logical disorder that has no established cure to date except
in a few patients who had successful bone marrow or stem
cell transplantation. Although gene therapy for sickle cell
anemia, the ultimate goal of cure, is not feasible at the
present, significant strides have been made at the basic level
to achieve the genetic correction of hemoglobinopathies [1].
The molecular lesion of the sickle hemoglobin is a point
mutation (GAG → GTG) in exon 1 of the β globin gene
resulting in the substitution of glutamic acid by valine at
position 6 of the β globin polypeptide chain [2, 3]. This
single-point mutation renders the sickle gene pleiotropic
in nature with multiple phenotypic expressions associated
with complex genetic interactions and modifiers that are not
well understood [2, 3]. The complications of this disease are
numerous and aﬀect every organ and/or tissue in the body.
Recently concise definitions of these complications have been
published [4] thus creating a uniform understanding of the
nature of these complications among providers, researchers,
patients and their families, and the community at large.
The definition of each complication was based on published
evidence if available and/or on the experience of experts in
the field. The definitions also included the diagnostic criteria,
severity index, and classification of each complication when-
ever available. Specific management and treatment of these
complications, however, were not described.
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The purpose of this paper is to briefly update the
definitions by including newly described complications and
review the accepted approaches for the management and
treatment of the major complications of sickle cell disease.
These will be based on published evidence if available and
on the experience of experts in the field. To that end
management of pain syndromes, hematological, neurolog-
ical, ophthalmological, pulmonary, hepatobiliary, splenic,
renal, genitourinary, musculoskeletal, and dermatological
complications will be addressed. Recently, there has been
increasing evidence that asthma predisposes to certain
complications of sickle cell disease including acute painful
crises, acute chest syndrome, pulmonary hypertension and
stroke [5]. Management of comorbid conditions, however,
will not be addressed except in certain situations where the
comorbid condition has a direct eﬀect on the manifestation
and management of the sickle cell complication in question.
It is hoped that that this paper together with the previously
published definitions will together constitute a review of
the state of the art on the complications of SCD and their
management.
1.1. Recently Reported Complications
1.1.1. Neurocognitive Impairment. Neurocognitive impair-
ment [4, 6] is an invisible complication of sickle cell anemia
(SS) that defies detection by imaging and other routine
diagnostic methods. Impaired neurocognitive function in
seemingly neurologically intact patients is not related to
vasoocclusion or hemolysis. It is detected by neuropsychi-
atric and neurobehavioral testing and is associated with
anemia and age.
A controlled cross-sectional multicenter study [6] com-
pared the neuropsychological function and neuroimaging
data from 150 adult patients of African descent with SS who
had no neurological symptoms with 52 community control
adults of African descent with Hb AA. The aﬀected patients
and controls were stratified by age and sex. The patients
with SS were anemic (hemoglobin levels <10 g/dL), whereas
the controls had normal hemoglobin levels. The primary
outcome of the study, mean nonverbal function assessed
by the Wechsler Adult Intelligence Scale III Performance
IQ Index, was significantly lower in patients than controls
(86.69 versus 95.19). Significant diﬀerences were also noted
in secondary measures including global cognitive function,
working memory, processing speed, and executive function.
Moreover, anemia was associated with worse neurocognitive
function in older patients. However, volumetric magnetic
resonance imaging measurements showed no significant dif-
ferences in total gray matter or volume of the hippocampus
between patients and controls, but there was a nonsignificant
reduction in brain volumes with older age among adults with
SS. Although lacunae were more frequent in patients with SS,
these lesions were not related to neurocognitive function.
Another uncontrolled study from a single institution [7]
showed that 11 adult patients with SCD had neurobehavioral
impairment independent of neuroimaging abnormalities.
Moreover, other studies [8, 9] reported neurocognitive
impairment in children with remote silent cerebral infarcts
(SCIs). Thus it is not clear whether neurocognitive impair-
ment is due to the anemia or to the infarct or both. Studies
are underway to determine if blood transfusion will improve
neurocognitive function of patients with and without SCI.
Other investigators [10], however, observed that regular
chronic blood transfusion does not prevent CSI or reverse
cerebral vasculopathy especially in patients with a history of
overt stroke.
1.1.2. Acute Silent Cerebral Infarcts (SCIs). The term “Acute
Silent” seems paradoxical since acuity is usually associated
with overt signs and symptoms whereas silence is associated
with covert findings. Nevertheless, in an observational study
[11] pediatric hematologists reviewed their experience with
acute SCI detected by diﬀusion-weighted MRI (DWI) in
children with SS. Their conclusion suggests that there is a
sequence of events that starts with an acute SCI that later
evolves into remote SCI. The acute event is most often
precipitated by severe anemia due to exacerbation of the
steady-state values. The severe anemia is associated with or
initiates cytotoxic edema in the brain which is visualized on
DWI as a hyperintense punctuate area of restricted diﬀusion
that corresponds to a decreased signal on the apparent
diﬀusion coeﬃcient (ADC) map. The DWI abnormal signal
appears within 24 hours of stroke onset and persists for 10–
14 days only. Later on, the usual T2-weighted abnormality
from the stroke develops and persists indefinitely as a remote
SCI. It is not clear how long it takes before the permanent
abnormality appears.
1.2. General Principles of Management of the Complications of
SCD. The complications of SCD are divided into threemajor
types: (1) pain syndromes and related issues; (2) anemia and
its sequelae; (3) organ or tissues damage. Management of
these complications will be described below. Management
of SCD in general and its complications in particular follow
five major approaches (Table 1). These include supportive
management, symptomatic treatment, preventative manage-
ment, and abortive and curative approaches to management.
Although these approaches apply to the disease as a whole,
at least one of them applies to each complication as will be
discussed below.
2. Management of Specific Complications
2.1. Management of Acute Anemia in SCD. The majority of
patients with sickle cell disease (SCD) have some degree of
baseline anemia due to ongoing hemolysis. Although there
is interpatient variability, individuals with hemoglobin SC
and sickle β+ thalassemia generally have less severe anemia
than hemoglobin SS and sickle β0 thalassemia. Certain
SCD-related complications, such as splenic sequestration,
aplastic crisis, and hyperhemolytic crisis, can lead to acute
exacerbation of anemia [12]. Below, we briefly describe
causes of acute anemia and discuss management of these
complications.
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Table 1: Approaches to the management of sickle cell disease and its complications.
Approach Definition
(1) Supportive management
Management intended to maintain the essential requirements for good health such
as balanced diet, sleep, hydration, and folic acid
(2) Symptomatic management
Management targeted to alleviate the symptoms of the disease as they occur. These
include blood transfusion for symptomatic anemia, analgesics for pain, and
antibiotics for infections
(3) Preventative management
Approaches to prevent the occurrence of complications of the disease. These
include things like vaccination, avoidance of stressful situations, Hb F induction
with hydroxyurea or other agents, and transfusion to prevent the recurrence of
stroke
(4) Abortive management
Major purpose of this approach is to abort painful crisis thus preventing them from
getting worse or precipitating other complication. The only promising abortive
approach has been nitric oxide
(5) Curative therapy
This is the ultimate goal of all inherited disorders. This has already been achieved in
SCD by stem cell transplantation. Gene therapy is another challenging goal
2.1.1. Acute Splenic Sequestration. The spleen undergoes
variations in size during childhood in SCD. It may be
initially enlarged in children with SCD but may become
dysfunctional as early as in first year of life. More than
90% of children with sickle cell anemia (SCA) may have
total loss of functional splenic tissue by early childhood
[13, 14]. Children with SCA who have not yet gone through
autosplenectomy, as well as SC disease and sickle beta tha-
lassemia, may be at risk for developing splenic sequestration.
Hemoglobin F likely plays a role in rate of spleen atrophy; as a
result individuals with high fetal hemoglobin concentration
retain splenic function longer than those with lower fetal
hemoglobin and remain susceptible to splenic sequestration.
Most cases of acute splenic sequestration occur between 3
months to 5 years of age, but it has been reported in infants as
young as 5 weeks [15] as well as in adults [16]. Acute splenic
sequestration is a significant cause of morbidity and could
be fatal in a few hours if left untreated, especially in children
[17]. Episodes of splenic sequestration in adults are generally
mild and have been reported in patients with hemoglobin
SC disease and sickle β+thalassemia at risk due to occasional
persistent splenomegaly into adulthood [18]. Early parental
education to identify splenic sequestration and seek urgent
medical attention in the event of symptoms of enlarging
spleen has been successful in reducing mortality associated
with this complication in SCD children [19].
Acute splenic sequestration in SCD results from the
trapping of red cells in the splenic sinuses which leads to
a sudden rapid enlargement of the spleen which could be
massive. These episodes are generally associated with viral or
bacterial infections. Patients present with pallor, tachycardia,
tachypnea, weakness, abdominal pain and distension, and
shock due to hypovolemia and acute decline in hemoglobin
level. Mild thrombocytopenia may also be present. The
cooperative study of sickle cell disease (CSSCD) defined
acute splenic sequestration as decrease of hemoglobin or
packed cell volume (PCV) of at least 20% from the baseline
along with increase in palpable spleen size of at least 2
centimeters from baseline [20]. Hepatic sequestration, which
is characterized by tender hepatomegaly, acute exacerbation
of anemia, reticulocytosis, and hyperbilirubinemia, can also
occur, though more rarely [21]. However, due to the limited
capacity of the liver to expand, hepatic sequestration is
generally not associated with cardiovascular collapse.
Acute splenic sequestration should be managed with
urgency due to its potential life-threatening nature. Imme-
diate treatment of acute splenic sequestration includes the
correction of hypovolemia to avoid hypovolemic shock and
the transfusion of packed red cells to maintain oxygen-
carrying capacity. Once the cardiovascular status is restored,
the patient improves rapidly and the spleen shrinks in few
days releasing the trapped red cell back into circulation.
Hemoglobin level increases often to a greater extent than
the predicted based on the red cell volume administered.
Therefore, to avoid hyperviscosity and related complica-
tions, patients should not be transfused to achieve baseline
hemoglobin levels.
The rate of recurrence of an acute life-threatening
episode of splenic sequestration is high, occurring in
approximately 50% of those who survive first episode [22].
To eliminate recurrence some have recommended elective
splenectomy after first episode [23] while others citing
concerns for postsplenectomy sepsis have suggested splenec-
tomy after two episodes of sequestration [24]. However in
situations when there is concern that child may not be
able to reach medical facility in time, splenectomy should
be strongly considered after the first episode of splenic
sequestration. Emergency splenectomy during an episode of
acute sequestration is not recommended. Partial splenec-
tomy has been considered as an approach for preventing
recurrences while retaining splenic function [25, 26]; how-
ever this approach is much less standard, and overwhelming
sepsis has been described in patient who underwent partial
splenectomy [27]. Since splenectomy may increase the risk
of invasive sepsis, all postsplenectomy patients should be
vaccinated against pneumococcus and meningococcus and
should receive lifelong penicillin prophylaxis. Limited-term
red cell transfusion has been recommended as a strategy to
delay splenectomy in young children under age 3 years [28].
While one study deemed short-term transfusion beneficial
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in reducing the risk of splenic sequestration and temporarily
reversing splenic dysfunction [29], another study found it
of limited value [30]. When considering chronic red cell
transfusion, the goal should be to maintain hemoglobin S
level less than 30%. Observation following an episode of
sequestration occasionally may be a reasonable strategy such
as in SCD adults in whom these episodes are generallymilder.
2.1.2. Acute Aplastic Crisis. In a steady state of health in SCD,
shortened lifespan of red cells remains compensated by an
increased production of erythroid cells by the bone marrow.
Thus even a temporary cessation of erythropoiesis in SCD
can lead to acute exacerbation of anemia. Suppression of
erythropoiesis can be caused by many infections, including
the classic example of parvovirus B19, which preferentially
attack erythroid precursors due to P-antigen of erythrocyte
being its receptor. Destruction of erythroid precursors leads
to severe anemia and reticulocytopenia [31].
The clinical course following Parvovirus B19 infection is
variable, and not all patients develop severe anemia. Episodes
of aplastic crisis are generally preceded by febrile illness.
Patients present with fatigue, pallor, and weakness along
with laboratory evidence of anemia and reticulocytopenia
(usually <1%) [4, 12]. Recovery generally occurs in a week.
During the recovery phase, patients develop brisk reticulocy-
tosis, which combined with anemia, may be misdiagnosed
as hyperhemolytic crisis. In patients presenting with red
cell aplasia serologic samples to confirm the Parvovirus B19
infection should be sent. Parvovirus B19 has been described
to be associated with other complications of SCD including
acute splenic sequestration [32], encephalopathy [33], and
acute chest syndrome [34]. Lifelong immunity develops
following a Parvovirus infection. Although many patients
recover from the transient erythroid aplasia spontaneously,
packed red cell transfusion should be considered for symp-
tomatic patients. The secondary attack rate of siblings with
SCD is high, so they should also be monitored closely
for development of aplastic crises. Additionally, patients
suspected to have Parvovirus infection should be isolated
from pregnant staﬀ because Parvovirus infection during
pregnancy can lead to hydrops fetalis [35].
2.1.3. Hyperhemolytic Crisis. Hyperhemolytic crisis is
defined as the presence of acute anemia along with
the evidence of accelerated hemolysis. It presents with
acute reduction in hemoglobin level often associated
with reticulocyte count that is higher than the baseline.
Several subphenotypes have been described including
hyperhemolysis during an episode of acute vasoocclusive
painful crises [36] or as an acute or delayed hemolytic
reaction following a transfusion of red cells [37, 38]. Acute
hemolysis can also occur in context of infection such as
malaria or drug exposure. Management is dependent on
the cause. Investigations should include evaluation to rule
out autoimmune hemolysis presenting as acute or chronic
hemolytic transfusion reaction where both autologous and
transfused red cells are destroyed [37]. Alloimmunization
increases the risk for hemolytic transfusion reactions. SCD
patients have higher incidence of RBC alloantibodies with
one reason being diﬀerences in the frequency of antigen
distribution between largely Caucasian donor pool and SCD
patients who are of African ancestry [28]. CSSCD reported
overall rate of alloimmunization to erythrocyte antigens
at 18.6% [39]. Risk of alloimmunization increases with
number of transfusions received by the patient [39].
Hyperhemolysis associated with painful crises can often
bemanaged conservatively, but transfusion of red cells can be
considered if clinically indicated. A high index of suspicion
is needed in case of transfusion-related hyperhemolysis,
because symptoms may be similar to painful crises including
bone pain and fever making the identification diﬃcult. It
is a serious and potentially life-threatening complication of
red cell transfusion. The laboratory evaluation in delayed
hemolytic transfusion reaction (DHTR) may reveal low
hemoglobin, elevated serum lactate dehydrogenase, and
bilirubin above the patient’s baseline. Serial hemoglobin
levels, reticulocyte counts, and hemoglobin electrophoresis
may be helpful in making a diagnosis of hyperhemolysis in
the posttransfusion setting. DHTR is often associated with
a positive antiglobulin test (DAT) [40]. The management
of posttransfusion hyperhemolysis is generally supportive.
Further transfusions should be avoided, as they often lead to
further hemolysis. However subsequent further transfusions
may be needed if hemolysis is rapid and severe. Additional
transfusions with corticosteroids and intravenous gamma
globulin have been successfully used in severe cases of post
transfusion hyperhemolysis [41–43]. Use of rituximab for
prevention of delayed hemolytic transfusion reaction has also
been reported in a patient with SCD [44].
3. Gastrointestinal/Hepatobiliary
Complications
Sickle cell disease aﬀects the hepatobiliary system in diﬀerent
ways at diﬀerent ages. Intrinsic disease results from recur-
rent ischemia and bilirubin stones. These result from the
vascular obstruction and red cell hemolysis of sickle cell.
Biliary sludge is a common finding that is often clinically
unimportant. Viral infections that aﬀect the liver may be
independent of or secondary to red cell transfusions. The
iron overload that accompanies red cell transfusions can lead
to liver dysfunction and fibrosis. Many medications taken by
sickle cell patients may cause or worsen hepatobiliary disease.
The dysfunction of the liver can aﬀect the lungs, kidneys, and
coagulation systems. Treatment is directed at the etiology of
the dysfunction as well as the underlying sickle cell disease.
The natural consequences of any hemolytic condition
aﬀect both the gallbladder [45] and the liver [46]. The gall-
bladder is aﬀected by hemoglobin (pigmented) stones [47],
biliary sludge [48–50], and obstruction [51–53]. The liver
is aﬀected by vasoocclusive changes (right upper quadrant
syndrome) of recurrent ischemia and reperfusion injuries
[46, 54], iron overload from transfusions that are used to
treat both symptomatic anemia and the complications of
sickle cell disease [55–59], vascular endothelial dysfunction
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[60], and the liver consequences of the hypercoagulation of
sickle cell [61–63].
The challenge physicians caring for sickle cell patients
is recognizing the life-threatening course from the more
frequent, similar appearing milder, recurrent syndromes. A
useful way to consider the protean eﬀects of hepatobiliary
issues in sickle cell is to consider the disorders of the
presentation and evaluation of abdominal complaints of
sickle cell followed by a review of the major disorders.
Although hepatobiliary conditions are intimately linked, the
embryology of the biliary system and the hepatic system
shows these two organs to be histologically and functionally
separate [64]. This explains the diﬀerential response of these
organs to the same insult. However, many conditions may
overlap, so a single diagnosis may mask parallel processes.
3.1. Right Upper Quadrant Syndrome. Acute pain in the
right upper quadrant is common in sickle cell patients [65–
67]. The symptom of hepatobiliary disease often must be
separated from the more common symptoms of sickle cell
disease. Patients develop sickle cell attacks in a consistent
pattern. The patient can often recognize whether the current
attack is diﬀerent from prior sickle cell pains. If the pain
is new, especially when accompanied by more jaundice
than usual, nausea and vomiting, then further hepatobiliary
workup is needed. Increasing nausea and vomiting with food
points to the gallbladder. Colic pains point to the gallbladder.
Right upper quadrant fullness with dull pains points to the
liver. General jaundice points to both.
3.2. Hepatomegaly and Ischemic Changes Are Common. The
liver is often increased in size throughout the life of the
patient [68]. If the liver has acutely increased in size, then
hepatic congestion or sequestration may be involved. A 1980
clinicopathologic study of 70 autopsies of sickle cell patients
found 91% with enlarged livers characterized by distention
of Kupﬀer cells engorged with red cells [69]. In 27% the liver
sinusoids were distended with obstruction from sickled red
cells. Focal necrosis of liver tissue was present in 34%. 20%
of patients had reparative liver changes of portal fibrosis and
regenerative nodules. The authors felt that recurrent vascular
obstruction, ischemia, necrosis, and repair best explained the
pathological findings.
3.3. Diagnostic Clues. If right upper quadrant pain is severe,
then acute swelling or inflammation may be involved. Mur-
phy’s sign is often lost in the general pains but, if present, may
point to the gallbladder. If the serum bilirubin concentration
is over 4mg/dL, then checking whether the fraction of direct
bilirubin exceeds 10% would point to the gallbladder as the
source of the increase [70, 71]. Some patients have genetic
variations in the UDP glucuronyltransferase that will elevate
the serum bilirubin concentration [72]. This recurrent or
chronic elevation should be evident on review of the patient’s
records. In most sickle cell presentations the AST is relatively
more elevated that the ALT, as the AST also reflects the
degree of hemolysis [73]. If the ALT is similarly elevated as
the AST, then a hepatocellular process may be occurring.
Similarly the alkaline phosphatase will be elevated in biliary
disease. However, bone infarcts will also call the alkaline
phosphatase to rise. Fractionating the alkaline phosphatase
into bone and biliary sources is seldom done. The clinical
presentation usually finds bone pain or severe extremity
pains with infarcts, and severe right upper quadrant pains
prompt imaging, usually ultrasound, of the hepatobiliary
system. Measurement of the aPPT and PT may provide
evidence of a more severe process beginning.
3.4. Key Points to Remember.
(i) Initial evaluation is for conditions that need emer-
gent transfusions or treatments.
(ii) Pain patterns that diﬀer from a patient’s usual pattern
need close evaluation.
(iii) Having sickle cell does not protect a patient from any
other condition.
(iv) Liver involvement may be part of a multiorgan failure
syndrome [74, 75].
(v) With any severe sickle cell complication, exchange
transfusions are often the treatment of choice [76–
79].
Hepatic crisis is often used as a general term to describe
right upper quadrant pain in a sickle cell patient [80,
81]. However, hepatic crisis is best used to describe a
syndrome consisting of pain, elevated ALT (usually less than
300 IU/liter), and hepatic enlargement. Another working
definition of a hepatic crisis could be painful hepatomegaly
and worsened jaundice (usually less than 12mg/dL) [82].
The definition used causes the incidence of this condition
to vary in reports. Large series reports that up to 10%
of patients admitted to hospital have hepatic involvement
rising to their definition of crisis. Other studies with more
restrictive definitions concluded hepatic crisis was rare. The
rapidity of the onset of symptoms and the rapidity of the
correction of ALT may be able to guide therapy. Symptoms
that began suddenly are more often typical, self-limited
sickle cell conditions. Symptoms that begin over several
days to weeks may be from more severe conditions such as
viral or autoimmune hepatitis, liver infarct, or gallbladder
dysfunction. Severe elevations of bilirubin (over 30mg/dL)
may represent acute liver failure of intrahepatic cholestasis
(see below).
If the condition is from typical sickle vaso-occlusion and
inflammation, then the elevation of ALT decreases after a
few days. Severe, persistent elevations may relate to hepatic
infarct, characterized by a wedge-shaped, hypointense CT
lesions [83]. Hepatic abscess has been rarely reported, but
should be suspected in a patient with fever, a course diﬀerent
from their usual sickle cell crisis, right upper quadrant
pain, and tender hepatomegaly [84–88]. Hepatic ultrasound
would delineate the abscess. Prior areas of hepatic infarction
give the bacteria a site to invade. Bacteroides species were
found in one report [85]. Bilirubin levels decrease to prior
values in about two weeks; liver transaminases return to prior
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values in about three months. If changes persist beyond those
times, further evaluation is needed.
Hepatic sequestration is best diagnosed by a rapid enlarge-
ment of the liver with a concurrent drop in hemoglobin
concentration [89–91]. The bilirubin also will be elevated
with a high percentage of direct bilirubin. Transfusions,
simple or exchange, may help reserve the process. Hepatic
sequestration may be a life-threatening event in pediatric
patients with sickle cell disease [89–91]. Small vessel con-
gestion with red cells leads to a drop in hemoglobin
levels. The liver enlarges and becomes tender and inflamed.
Treatment is transfusions. Often the hemoglobin level is
low enough that given red cell units (matched for ABO,
Kell, E, and C antigens) to raise the hemoglobin to 9 g/dL
often stabilize the process. Manual or automatic red cell
exchanges are indicated for more severe cases shown by
hepatic dysfunction or a hemoglobin level over 9 to start
with. Hepatic sequestration may be part of the multiorgan
failure syndromes [74, 75].
Chronic hepatic sequestration has been reported in
a 17-year old with SS hemoglobin [92]. After exchange
transfusions, his liver size decreased. However it recurred.
This recurrence was successfully treated with hydroxyurea for
several months.
One report of “reverse sequestration” occurred following
simple transfusions. This syndrome comprises a sudden
increase in hemoglobin concentration, sudden onset of
hypertension, acute congestive heart failure, neurologic signs
of infarct or hemorrhage [93].
Autoimmune hepatitis is reported in sickle cell patients
[94, 95]. Interestingly, it also appears in mice models of sickle
cell disease (personal communication).We have documented
transient positivity of antibodies to smoothmuscle (antiactin
F). Associated features of autoimmune hepatitis include
rashes, skin ulcers, and joint disease. The etiology, natural
course, and treatment of autoimmune hepatitis in sickle cell
patients are unclear. If a patient has persistent liver symptoms
and antibody titers to smooth muscles, then a therapeutic
trial of prednisone and azathioprine may be warranted.
Referral to a hepatologist is indicated.
Viral hepatitis occurs at least as frequently as in the
general population [96]. Hepatitis C, and to a lesser extent,
Hepatitis B, occurred more often because of blood product
exposure. Improved blood product testing has reduced the
incidence of these infections, but they still occur. We screen
all our patients yearly for Hepatitis C viral RNA by PCR.
In new patients, persistently elevated ALT levels require
screening for viral hepatitis. Every sickle cell patient should
be vaccinated with two doses of Hepatitis A vaccine from
six months to a year apart and three doses of Hepatitis
B vaccinations at zero, one, and six months. Quantitative
hepatitis B surface antibody tests and total Hepatitis A
antibody tests are available to help decide if a patient has
been adequately vaccinated if the records are not available.
Many practitioners opt to revaccinate in case of any doubt.
No vaccine exists for Hepatitis C prevention. Patients with
chronic Hepatitis B and Hepatitis C should be treated as
any other patients. There has been some concern about
using ribavirin because it may cause hemolytic anemia. If a
patient on ribavirin does develop worsening anemia, then
placing the patient on monthly transfusions would both
allow therapy to continue and would decrease sickle cell and
anemia symptoms. A recent article showed good results in
treating sickle cell patients for chronic hepatitis C [97]. Liver
transplants are as successful in patients with sickle cell disease
and other patients needing allographic livers [98–101].
Hepatic siderosis is a growing area of concern and research
[102]. As red cell transfusions become routine for more
indications, the inevitable result is the accumulation of liver
iron. After about a year of transfusion therapy, serum ferritin
levels rise to over 1,000 ng/mL. While serum ferritin is a
rough guide to total liver iron, values over 1,000 indicate liver
iron overload. Other studies have shown significant liver iron
accumulation after 13 units of red cells. Each unit of red cells
contains nearly a year worth of dietary iron. Overmany years,
hepatic dysfunction, insuﬃciency, fibrosis, and cirrhosis may
lead to morbidity and even liver death. Many patients on
regular transfusions will have hyperintense livers on CT scans
or hypointense livers on MRI scanning [103, 104]. These
changes have been used to semiquantitate the degree of iron
loading. Chelation with deferoxamine [55, 105], deferasirox
[106], or deferiprone (recently approved in the US) does
reduce total body iron. However, all regimes have issues
with compliance and side eﬀects that require appropriate
monitoring. When patients with iron overload are admitted
to hospital with noninfectious complaints, we often give
deferoxamine 3 grams in 500mL normal saline intravenously
over 24 hours, repeating continuously during their stay.
Giving Vitamin C 250mg orally daily while the patient is on
deferoxamine increases iron excretion [107, 108]. Ongoing
cohort studies should help define the natural history of iron
overload in sickle cell patients [109–111].
Hepatic eﬀects on kidneys and lungs are increasingly
recognized. Although there are few publications concerning
sickle cell patients, such eﬀects are well known in other
conditions where the liver is cirrhotic or dysfunctional. The
hepatorenal syndrome [112], hepatopulmonary syndrome
[113], and the portopulmonary [114] syndrome may com-
plicate the hepatic disease of sickle cell.
Sickle cell intrahepatic cholestasis or sickle cell hepatopathy
is a condition with marked hyperbilirubinemia (>50mg/dL)
and a high fraction of direct (conjugated) bilirubin (about
50%) [77, 115–118]. Other features of right upper quadrant
pain and progressive hepatomegaly resemble many of the
hepatic crisis syndromes. However, in sickle cell intrahepatic
cholestasis, the liver transaminases are nearly at baseline.
Coagulopathy as assessed by the PT test is often found. Renal
insuﬃciency is often present, likely from the nephrotoxic
eﬀects of bilirubin. Endoscope retrograde cholangiopan-
creatography has been reported to guide management by
diagnosing strictures from ischemic cholangiopathy and
defining the presence or absence of common bile duct stones
[119]. Some authors consider the presence of acute sickle
hepatopathy to contraindicate liver biopsies [120]. Ischemic
cholangiopathy has also been described [121].
Early reports indicate that sickle cell intrahepatic
cholestasis was a life-threatening condition that mandated
exchange transfusions. As clinicians were more aware of the
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condition, series were reported that had a less severe course
[122]. Given the protean causes of intrahepatic cholestasis, it
is reasonable to divide cases of cholestasis into those with and
those without other evidence of marked hepatic dysfunction
and coagulopathy. The milder cases (bilirubin level 10 to
30mg/dL) appear to be more common in children. Patients
in the first category should be monitored for worsening
hepatic function: encephalopathy, coagulopathy, and rising
bilirubin concentrations. For the more severe cases, exchange
transfusion may be given, but it is not always eﬀective [77,
79].
Cholelithiasis occurs as early as two years old [47].
About 30% of patients will have gallstones by 18 years of
age [52, 123, 124]. The incidence and prevalence of this
condition appears to be aﬀected by local diet and possible
genetic factors [125]. The coinheritance of α-thalassemia
may reduce the incidence of stones since it may lessen the
degree of hemolysis that is thought to drive stone formation
[126]. The cause of cholelithiasis is usually pigmented stones
resulting from the breakdown of hemoglobin [45]. Some
reports implicate ceftriaxone and other third generation
cephalosporins as causing crystallization in the gallbladder
[127]. However, these antibiotics are commonly and use-
fully used in the proper settings. In adults, asymptomatic
gallstones are common and are best treated by observation
only [52, 53, 68, 123]. Abdominal and right upper quadrant
pains are common in sickle cell patients. Cholecystectomy for
recurrent right upper quadrant pains often does not relieve
the recurrent symptoms. Only if signs of cholecystitis (fever,
increased direct bilirubin, and positive imaging) develop,
should cholecystectomy be considered after the treatment
with supportive care and antibiotics [47, 124]. Laparoscopic
cholecystectomy is the procedure of choice for this indication
[128, 129]. This also causes less abdominal muscle disruption
and decreases postsurgical complications including acute
chest syndrome. Ultrasound is the imaging of choice but
is not diagnostic in most cases. Reports of pancreatitis
from sickling also exist. Biliary scintigraphy is seldom used
because of the numerous false positive results [130, 131].
Still, it has a useful negative predictive value if used in the
right setting. Technetium scanning may show hyperemia of
cholecystitis but its use is not well studied. Liver peliosis and
extramedullary erythropoiesis have occasionally been noted
as multiple nodules on liver imaging [132].
Biliary sludge is a common finding in sickle cell patients
[48, 50]. Biliary sludge is nonshadowing, echogenic intralu-
minal sediment. This material is calcium bilirubinate, choles-
terol crystals, viscous bile, mucus, and proteins. The natural
history of biliary sludge in children with sickle cell disease
finds that at a mean of 2.1 years of followup, about 65%
of such patients do eventually develop gallstones, although
not necessarily symptomatic ones. About 40% of patients
originally with biliary sludge do not develop gallstones,
despite the continued presence of sludge in most [133].
Most authors recommend yearly ultrasounds to access stone
formation. They reserve cholecystectomy only for patients
with signs and symptoms of acute cholecystitis [133].
Choledocholithiasis also occurs in sickle cell disease [51].
Even in patients with cholecystectomy, recurrent stones may
form in the common bile ducts. Symptoms are similar
to primary gallbladder disease. Ultrasound may be the
best modality to evaluate the common bile duct. Duct
obstruction is seldom complete. This may be because
pigmented stones are smaller than nonpigmented stones.
If the common duct is obstructed, then symptomatic or
chemical pancreatitis may be the presentation [134]. After
cholecystectomy, the common bile duct is usually dilated,
confounding diagnosis of new stones. Given the prevalence
of common duct stones, patients with persistent cholestatic
jaundice should have imaging to evaluate the ductal system.
If surgery is contemplated, some authors suggest ERCP as the
best approach to determine management [135].
Acute cholecystitis presents as it does in patients without
sickle cell disease [53, 136]. Right upper quadrant pain, fever,
nausea, and vomiting have a long and diverse diﬀerential
diagnosis. When the diagnosis is suspected, then ultrasound
is the usual next step. Imaging signs of acute inflammation
or obstructing stones prompt treatment for pain, hydration,
and the assessment for infection. Laparoscopic cholecys-
tectomy is deferred until the acute episode is over. If all
the stones and sludge have cleared, then surgery may not
be indicated. Some authors prefer a conservative approach.
Intraoperative cholangiography is reported to have a 25%
false positive rate. Some authors recommend intraoperative
ERCP. A detailed intraoperative evaluation of the biliary
system is important as symptoms often persist or recur after
cholecystectomy [124].
Chronic cholecystitis may be related to persistent gall-
stones or persistent biliary sludge. Recurrent symptoms
consistent with colic warrant screening with blood work
and imaging. If the blood work shows increases in conju-
gated (direct) bilirubin during the attacks, and there are
ultrasonographic signs of a thickened gallbladder wall, then
cholecystectomy may decrease these symptoms. However,
just as in chronic cholecystitis in the general population, the
symptoms may recur several months after surgery.
3.5. Summary. Disorders of the hepatobiliary symptoms are
common in sickle cell disease. Besides the conditions found
in the general population, several conditions occur that
are specific to sickle cell disease. These conditions include
the prevalence of pigmented stones, intrahepatic cholestasis,
hepatic sequestration, and recurrent hepatic ischemia and
necrosis. A directed history and physical examination will
suggest needed further evaluations. Laboratory values and
imaging will often establish the diagnosis. Cholecystectomy
is best reserved for symptomatic patients. Biliary sludge
should be followed for the development of symptoms. For
any severe or multiorgan dysfunction in sickle cell patients,
red cell transfusions or exchange transfusions will stabilize
the underlying sickle cell disease and may reverse the
pathologic process.
4. Muscular/Skeletal/Skin Complications
4.1. Dactylitis. Dactylitis is usually the earliest musculoskele-
tal manifestation of SCD and occurs in infants and very
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young children with a peak incidence during the first 6–12
months of life [137]. Prevalence rates of dactylitis are roughly
45% before age 2 years. It occurs more often during cold
seasons and is associated with a lower fetal hemoglobin and
higher reticulocyte counts [138]. In the CSSCD study [139,
140] similar to the Pediatric Cohort of Guadeloupe 1984–
1999 [141] dactylitis particularly occurring prior to age 6
months was a predictor of adverse outcomes including death,
ACS, stroke, and frequent pain [142]; however this was not
reproduced in the Dallas cohort, and dactylitis has limited
utility as a predictor of outcome [143]. Ischemia/infarction
of the bone and marrow is associated with increased
erythropoiesis and bone marrow expansion involving the
hands and feet and results in tenderness, swelling, redness,
and warmth of the aﬀected limb/digit. Bony destruction of
the terminal phalanges and metacarpals may occur from
prolonged ischemia and or superimposed osteomyelitis. The
administration of malaria prophylaxis was found to reduce
the number of episodes of both malaria and dactylitis
[144]. The mainstay of treatment for dactylitis remains
oral or parenteral nonsteroidal anti-inflammatory agents
and aggressive intravenous hydration. Opioid analgesics
provide additional pain control as needed, and topical warm
packs may help ease discomfort and swelling. Attention
to treating coexisting infection and ruling out secondary
osteomyelitis of aﬀected bones is prudent. In the recently
reported BABY HUG randomized controlled trial, the use of
hydroxycarbamide resulted in a significant reduction in the
rates of dactylitis in very young children with SCD (24 events
in 14 patients versus 123 events in 42 patients in the placebo
group, P > 0.0001) [145].
4.2. Osteopenia/Osteoporosis. Osteoporosis (OP) and low
bone mineral density (BMD) or osteopenia is now being
recognized as a common bone complication in both children
and adults with SCD. The prevalence of low BMD in SCD
ranges from 30 to 80% [146–151] with a predilection for
the lumbar spine. Increased hemolysis, (low hemoglobin,
high LDH, high reticulocyte count), hemoglobin F, age, sex
hormone status, number of vaso-occlusive events, and body
mass index (BMI) have all been correlated with BMD in
SCD [152–155]. Often a normal BMD at the femoral neck,
particularly in a patient with avascular necrosis may give false
reassurance representing local increase in bone remodeling
in response to infarction and necrosis. Fractures involving
the long bones and spine are grossly underdiagnosed in
SCD in part due to the high rates of pain from other more
common etiologies (acute vaso-occlusion, bone infarcts,
osteonecrosis, and chronic marrow expansion). Thus the
expected relative risk of fractures based on the high preva-
lence rates of OP in SCD has not been documented. Only
one published report compares fracture rates among persons
with SCD and thalassemia patients and showed similar
fracture rates for SCD and the general population [156]. This
raises the question as to whether the clinical outcomes of OP
may be modulated by the vaso-occlusive phenomena seen
with SCD. Many times, radiographs are not obtained with
exacerbation of pain symptoms as it is assumed to be typical
vaso-occlusive pain that is characteristic of the disease. Also,
both clinicians and radiologists are usually underwhelmed
by the presence of so-called sickle cell bony changes on plain
radiograph as these are seen almost universallymaking it easy
to overlook subacute and chronic fractures or osteopenia.
The specific etiology of osteoporosis in SCD is multifac-
torial with many similarities to the OP found in thalassemia
syndromes albeit less well studied [157, 158]. Hypogo-
nadism (delayed puberty and/or secondary hypogonadism
associated with hemosiderosis) is a well-recognized cause
of OP and is associated with increased bone turnover
[159]. Delayed constitutional growth and maturation asso-
ciated with IGF-1 deficiency, hypothyroidism as well as
micronutrient deficiencies are also commonly seen in SCD
and negatively impact optimal bone mass accrual [160,
161]. Bone marrow expansion from chronic anemia and
increased erythropoiesis, increased bone turnover from
vitamin D deficiency, recurrent bone infarcts and vaso-
occlusion, chronic inflammation as well as sedentary lifestyle
due to pain all contribute to development of osteoporosis
in SCD [162–166]. Iron overload has both direct and
indirect eﬀects on bone density. Directly, increased iron
deposition in bone marrow leads to chronic inflammation,
inhibition of osteoblast function, and increased osteoclast
activity leading to bone resorption, cortical and trabecular
bone abnormalities [167–169]. Iron overload by its eﬀect on
endocrine organs leads to hypogonadism, hypopituitarism,
and ultimately reduced BMD [155, 156, 160, 161, 164, 165,
170]. Genetic determinants of BMD have been investigated
in several populations and groups but are not well studied in
SCD. Polymorphisms of the vitamin D receptor (VDR) and
collagen type I alpha 1 gene (COLIA1) have been associated
with reduced BMD in postmenopausal and thalassemia
and predispose women to osteoporotic fractures [171–174].
These correlations, however, have not been confirmed in
SCD.
According to the World Health Organization (WHO)
to be diagnosed with osteoporosis, one must have a bone
mineral density (BMD or bone mass) of at least 2.5
standard deviations (T score) below the peak bone mass
typically achieved by a healthy adult between the ages of
18–30 years of age of the same sex and ethnicity [175]
(WHO Scientific Group on Prevention and Management of
Osteoporosis 2000: Geneva, Switzerland, 2003. “Prevention
andmanagement of osteoporosis: report of aWHO scientific
group”). A z-score is used to report BMD that is corrected for
age as well as sex and ethnicity; therefore it is more applicable
to pediatric subjects. Regardless of definition, the high rates
of low BMD in SCD predispose to fractures and deterioration
of bone; however a consensus on how to manage low BMD
in SCD currently does not exist.
The implications of low BMD to the aging patient
with SCD are far reaching. Osteoporosis is frequently
asymptomatic; when fractures occur, they cause significant,
morbidity including pain, deformities and vertebral collapse
[176]. Requirement of long-term analgesia, mechanical
support, and surgical interventions increases exponentially
following OP-related bone complications. The literature
on fracture prevalence in SCD is however very limited
The Scientific World Journal 9
[156, 177–179]. A study by Fung et al. found the self-
report rates of fracture among young adults (median age 25
years) with SCD to be 32% and 28% for nontransfused and
transfused males and 15% and 16% for nontransfused and
transfused females, respectively [156]. In this report, most
fractures occurred in the upper extremities (47.4%), lower
extremity (29.5%), or spine and pelvis (11.5%), and fracture
rates increased with age. Ebong reported fracture rates of
20% in persons with SCD and osteomyelitis, the majority of
whom were children [179]. As the natural history of SCD
continues to evolve, the prevalence of age-related diseases
such as OP will be better known. This is significant because
hip fractures are associated with a one-year mortality rate of
36% in men and 21% in women [180]. Prospective studies
on the prevalence of fractures and pain that is attributable
to OP in SCD are desperately needed to inform treatment
guidelines and interventions.
The current management recommendation for OP in
SCD is borrowed from the endocrine and thalassemia
literature with an emphasis on primary prevention. Adequate
vitamin D and calcium intake starting during skeletal devel-
opment in childhood, encouraging weight-bearing exercise,
early detection and treatment of hypogonadism or growth
hormone deficiency, prevention and treatment of iron over-
load, are strategies that should be incorporated into routine
SCD comprehensive care [157]. Prospective screening for OP
annually (using dual energy X-ray absorptiometry (DEXA)
of at least 2 separate sites) once patients reach age of
anticipated peak bone mass is suggested to detect early
deterioration in BMD [148, 181]. A detailed musculoskeletal
evaluation should also be performed to rule out fractures
of at-risk sites (hips, shoulders, and spine) particularly
when vaso-occlusive pain becomes prolonged and poorly
responsive to usual therapies as the occurrence of OP-related
fractures may due to SCD has not been previously reported.
Studies in thalassemia subjects suggest eﬃcacy in reducing
bone turnover with modest gains in BMD at lumbar
spine but not femoral neck [157, 182]. A meta-analysis of
seven clinical trials of bisphosphonates for secondary OP
in children by Ward et al. concluded that the evidence
was insuﬃcient to support its use as standard therapy and
supported the need for further evaluation [183]. In adults,
however, bisphosphonates are widely used for secondary OP
with acceptable eﬃcacy and tolerability [184, 185]. There are
currently no consensus guidelines for their use in SCD for
treatment of secondary OP. Hormonal supplementation for
hypogonadism may be eﬀective in preventing and halting
progression of OP in SCD; however concerns for increased
risk of thrombosis (in females) and priapism (in males)
will need to be addressed by further research [186–188].
Rigorous prospective studies of these agents in adults and
children with SCD are needed to determine their short- and
long-term safety, tolerability and eﬃcacy in prevention and
treatment of OP.
4.3. Myositis/Myonecrosis/Fascitis. Acute vaso-occlusion in-
volving muscles, tendons, and fascia can occur in SCD
[189]. It is seen in individuals with prior history of severe
prolonged vaso-occlusive episodes and typically low
hemoglobin F%. Anecdotal reports in adolescents suggest
strenuous activity and muscle overexertion as seen with
competitive dancing, video gaming, and other sports may
contribute to the increasing incidence of sickle myositis
and myonecrosis. The pattern of muscle involvement is
usually symmetric and involves most often the proximal
muscle groups [190]. Acute VOC involving muscles leads
to myositis, myonecrosis, and eventual myofibrosis, which
can result in long-term sequelae including contractures,
indurations, and muscle atrophy. Patients usually present
with acute focal pain, tenderness, and swelling of discrete
muscles or groups of muscle/compartments that is out
of proportion to their usual pain crisis and described as
“diﬀerent” from a typical sickle pain episode. Progression
to involve the underlying fascia culminates in an acute
compartment syndrome [191]. Superinfection with
Staphylococcus aureus, Streptococcus pneumoniae, or other
organisms may occur with spread to underlying bones
and joints leading to progressive organ damage, sepsis,
and multiorgan failure. Detection of an elevated LDH,
CPK, (muscle fraction) and myoglobin in serum may be
suggestive; however it is not present in all cases. Elevated
CRP may suggest concurrent infection and warrants empiric
antibiotic therapy. Confirmation is made by evidence
of muscle inflammation and necrosis by MRI or on
muscle biopsy showing inflammation, edema, and necrosis
of muscle fibers with collagen deposition and fibrosis
[190, 192].
Although myositis, myonecrosis, and fasciitis are diﬃcult
to distinguish clinically, initial treatment modalities are
the same and include bed rest, short-term immobilization,
intravenous fluid hydration, anti-inflammatory agents, and
opioid analgesics for pain relief [193]. There is not much
written in the literature on the optimal management of
this complication in SCD; however in diabetic myonecrosis,
exercise or physical therapy typically exacerbates pain and
extends infarction, so should be avoided [193]. Very rarely
with myofasciitis, an acute compartment syndrome may
occur requiring surgical intervention to decompress the
muscle compartment and/or excise any calcified necrotic
material that would compromise organ perfusion. The
novel use of low-level laser phototherapy is currently being
investigated in animal models of ischemic muscle injury as
a therapeutic modality to reduce myonecrosis by promoting
muscle repair and angiogenesis targeting type I and III col-
lagen fibres [194]. Other novel therapies are being evaluated
for their benefit in sickle ischemia reperfusion injury such
as is seen with myonecrosis and include anti-inflammatory
agents such as sulphasalazine, an NFκB inhibitor and IVIG
[195]. Sulfasalazine is believed to reduce expression of
VCAM, ICAM, and E selectin on endothelial cells in the
microcirculation and attenuate the eﬀect of reperfusion
injury thereby improving microcirculatory blood flow in
sickle mice, while IVIG is believed to reduce leukocyte adher-
ence to endothelium and improve microcirculatory blood
flow in transgenic sickle mice [196, 197]. Further research
on the applicability of these interventions in humans is
warranted.
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4.4. Avascular Necrosis (AVN). The complete disruption of
vascular supply to the articular surfaces and ends of long
bones, particularly the femoral and humeral head and
spine, results in avascular necrosis or AVN [146, 198, 199].
Scientific advances in chronic bone disease have lagged
behind the impressive improvements in survival for SCD,
and AVN remains the leading cause of crippling disability
in this population [146, 198, 200–204]. Approximately 50%
of individuals with SCD will develop some form of bone
fragility syndrome (osteonecrosis (AVN), compression spine
fractures) by age 35 years. Consequently, AVN is a major
cause of frequent hospitalizations, increased health care
utilizationts, and poor quality of life in these patients [198,
205–208]. In adolescents and adults with SCD AVN typically
involves the epiphyseal bones of the hip, shoulder, and spine;
however any joint could be aﬀected. Risk factors for AVN
include recurrent vaso-occlusion (VOC), male gender, high
hemoglobin, low hemoglobin F, vitamin D deficiency, and
alpha thalassemia trait [162, 201, 207, 209–218].
Recent studies in SCD suggest a 26% prevalence of AVN
among children with hemoglobin SS (mean age 9.8 years),
and in adults it is 48.6% with a mean age of 26.7 years with
a four-year progression rate of 67% [205, 212]. In a report
by Ware et al., 41% of adults with hemoglobin SS over the
age of 15 years had AVN of a bone [219]. Koduri et al.
reported that silent AVN occurred in 41% of children aged
4–28 years with spine and shoulder involvement occurring
in 27% and 28% cases, respectively. Fourteen to 23% of
individuals with Hgb SC develop AVN [211]. In Jamaica,
Lee et al. reported that the likelihood of developing AVN
was 82% between the ages of 10 and 29 years [220]. Earlier
reports on the prevalence of AVN in SCD were grossly
underestimated particularly since 47% of patients with hip
disease and 79% with shoulder disease had no symptoms
at diagnosis [198, 215]. Bilateral hip involvement is seen
in about 40–91% of SCD patients with femur AVN with
a 3–5 year progression time to complete collapse (without
intervention) particularly in older adolescents and adults
who typically fail conservative management and develop
a secondary degenerative arthritis [202, 217, 221–223].
Progression to complete joint collapse is usually rapid even
in asymptomatic cases, and results of joint replacement are
quite poor [202, 224, 225].
Early diagnosis of AVN is of critical importance as
outcomes of conservative management are dependent on
disease severity. A multidisciplinary approach preferably in a
specialized center with expertise in SCD is needed to achieve
optimal treatment outcomes and should involve orthopedics,
hematology, physiotherapy, and nutritional expertise [146].
Treatment goals are primarily to relieve symptoms, pre-
vent disease progression, and improve function of aﬀected
joints. Non-weight-bearing exercises that strengthen the
aﬀected limb girdle and improve range of motion are
recommended. Presence of nutritional deficiencies that
aﬀect bone growth and development should be ruled out
particularly in children such as vitamin D and zinc deficiency
and protein energy malnutrition. Failure of conservative
measures and/or progression to joint collapse, fractures,
or debilitating pain necessitates surgical interventions such
as core decompression, arthroscopy, arthroplasty, or total
joint replacement (TJR). Perioperative management for
orthopedic procedures in sickle cell patients should include
attention to hydration and oxygenation, simple or exchange
transfusions, and close monitoring for hypoxemia, develop-
ment of vaso-occlusive crisis and acute chest syndrome [226–
229].
The use of core decompression although established as
an eﬀective treatment for stage 1 AVN was showed to have
no superiority over intensive physiotherapy in a randomized
controlled trial (National Osteonecrosis Trial in Sickle Cell
Anemia Study Group) [206, 230]. Novel therapies currently
under investigation for early stage AVN include extracor-
poral shock wave therapy [231, 232]. Stem cell therapy is
a promising new method in the management of stage 2
and 3 disease (with or without osteotomies) and utilizes
vascularized bone grafts and/or autologous volume reduced
bone marrow injected into femoral head following core
decompression to promote healing and revascularization of
aﬀected bone and joint [233].
The treatment of stage 4 disease is more complex, and
depending on size and location of the necrotic zone and
the pathology of the adjacent bone, resurfacing or short-
stem hip arthroplasty can be performed. Conventional total
joint replacement (TJR) is still however the gold standard.
This poses a challenge for the younger patient before the
second decade of life who continues to have longitudinal
bone growth in the unaﬀected limb and is more active
resulting in length discrepancies, prosthesis instability, and
muscle imbalance. There have been conflicting reports on
the success of joint replacement surgery for severe AVN in
SCD, and prosthesis failure is especially common in these
patients. The typical lifespan of a replaced joint is 5–10
years with individuals suﬀering loosening of the prosthesis
over time. Patients may continue to have continued pain
and limitations of mobility even after arthroplasty. A recent
review reported a revision rate of 31–63% with less than ten
years of followup compared to 10% in nonsickle patients
[201, 217, 234–236]. The longevity of a replaced hip has
increased significantly with modern surgical techniques,
modern implants that use materials such as ceramic and
polyethylene, and improved disease management strategies
with a concomitant reduction in complication rates [236].
The use of chronic hypertransfusion (CHT) and hydrox-
ycarbamide (HU) to modulate disease severity and prevent
sickle vaso-occlusive complications has not been shown
to conclusively reduce the risk of AVN in SCD [237].
On the contrary, there are reports of new and worsening
AVN among SCD patients on HU [238–240]. Prospec-
tive screening for AVN using standardized tools such
as the Children’s Hospital Oakland Hip Evaluation Scale
(CHOHES) should be incorporated into comprehensive
care for all individuals with SCD [241]. Larger prospective
longitudinal studies are needed on the incidence, prevalence,
risk factors, and progression rates of AVN with various
interventions in the hydroxycarbamide era. Randomized
controlled trials of improved joint and spine rehabilitation
techniques in SCD would shed more light on optimal
therapeutic options.
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4.5. Leg Ulcers. Ulcerations of the skin and underlying tissues
may occur in SCD most commonly involving the medial
and lateral aspects of the ankle. Delayed healing leading to
skin ulceration may also occur at postsurgical sites of after
mild trauma. Risk factors associated with the development
of leg ulcers in SCD include trauma, infection, severe
anemia, high hemolytic rate (elevated LDH and reticulocyte
count, low hemoglobin and hemoglobin F), geographic
location, socioeconomic status, and venous incompetence
[242–244]. Recent studies have proposed an association
between hemolysis-induced vasculopathy and a hemolytic
subphenotype in SCD that presents clinically with increased
incidence of leg ulcers, pulmonary hypertension, and pri-
apism [245]. Genetic factors such as HLA B3 and Cw4 are
associated with a 17-time increase risk of leg ulcers in SCD
[246]. Various candidate gene and genome wide association
studies on leg ulcer susceptibility in SCD are ongoing [247].
The epidemiology of leg ulcers in SCD is not well defined
as the clinical impact on patients is often underestimated
by clinicians since it is not immediately life-threatening
complications. Environmental factors and geography influ-
ence the prevalence of leg ulcers, and in the Unites States
approximately 2.5% [242] of persons with SCD will present
with a leg ulcer whereas in Africa the range is 1.5–13.5%
and in Jamaica it is over 40% [246, 247]. Patients with
leg ulcers are typically older in age, have homozygous SS
disease, and present with large ulceration areas (median
diameter of 12.4 cm) that have persisted for prolonged period
of time (median duration of 29 months) [243]. Common
sequelae include superinfection, ankle stiﬀness and edema,
osteomyelitis, pathological fractures, severe pain, mood
disorders, and poor-health-related quality of life [243].
The pathogenesis of chronic leg ulcers in SCD is poorly
understood and quite complex. Factors that predispose to
chronic ulceration in SCD include poor skin perfusion (due
to mechanical obstruction to flow from vaso-occlusion),
increased local edema from venous incompetence, abnor-
mal autonomic vascular control (inadequate venoarterial
response to leg lowering and secondary venous hyperten-
sion) [248], microvascular thrombosis, decreased oxygena-
tion, reduced nitric oxide bioavailability (impaired endothe-
lial function), and minor trauma [246, 249]. Histopatholog-
ical sections of sickle leg ulcer biopsies show similarities to
diabetes and vascular disease-related ulcers with intimal pro-
liferation, neovascularization, and perivascular proliferation
at the base of the ulcers suggesting a role for thrombosis.
Raised edges with hyperpigmentation and hyperkeratosis are
characteristic, and ulcers may penetrate deep into fascia or
even involve periosteum of bone.
Primary prevention is the main focus of the management
of leg ulcers in SCD. A detailed review of prevention
strategies and the treatment of leg ulcers by Eckman provides
practical management insights [246]. All patients with SCD
should be educated on avoiding ill-fitting shoes and even
minor trauma to extremities (such as insect bites, use of
extremities for drawing blood or intravenous therapy) with
prompt treatment if trauma does occur [246]. The use of
support stockings with limb elevation for edema, emollients
to prevent cracking and drying of skin, and the use of cotton
socks over nylon or synthetic fibers are commonly used
secondary prevention strategies.
Once an ulcer is established, treatment can be very frus-
trating for both patient and medical team. A multipronged
approach that provides for gentle debridement (with Duo-
Derm hydrocolloid dressings, Unna boots), prevention and
control of local edema, control of infection, provision of a
local healing environment with topical agents, and systemic
treatment of the disease and other identified micronutrient
deficiencies has provided the best treatment outcomes. Zinc
is a trace element that plays an important role in immune
function and wound healing. Small but randomized studies
have shown eﬃcacy of oral zinc sulfate 220mg three times
a day in promoting rapid healing of leg ulcers [250]. This
may be particularly useful in individuals with SCD who have
high rates of zinc deficiency. Skin grafts and myocutaneous
flaps have been used for recalcitrant ulcers resistant to local
therapy; however results are equivocal as there remains a
high risk of thrombotic occlusion of graft microvasculature
[251]. Short-duration chronic hypertransfusion therapy may
reduce anesthetic risk and improve chances of graft success
along with anticoagulants and or antiplatelet agents [249,
252]. Topical antibiotics have been shown to improve healing
time compared to controls; however the use of parenteral
or oral antibiotics is reserved for ulcers complicated with
systemic infection or osteomyelitis [253].
Chronic leg ulcers will recur between 25 and 50%
of the time, and retreatment will be needed. There are
several anecdotal [254] reports on the use of hyperbaric
oxygen, arginine butyrate, topical herbal applications, and
topical growth factors in the treatment of SCD leg ulcers
without randomized trials to confirm their utility. Recent
advances in themanagement of leg ulcers in diabetics include
topical applications of analgesics, including opioids for pain
[255], topical application of a platelet-derived growth factor
prepared either by autologous (Procuren) or by recombinant
technology (Regranex) [256], and the use of cultured skin
grafts. The eﬃcacy of these agents will need to be confirmed
by randomized clinical trials in SCD.
4.6. Osteomyelitis/Septic Arthritis. Bacterial infections in-
volving the cortical bone (osteomyelitis) and joint space
(septic arthritis) have been commonly reported in SCD,
particularly in association with avascular necrosis and bone
infarcts [257, 258]. The prevalence of OM is lower in
individuals with the Bantu haplotype, and it may occur
as a complication of severe leg ulcers [259]. The most
common etiologic organism in sickle OM is salmonella
followed by Staphylococcus aureus and enteric gram-negative
bacilli [260, 261]. The femur, tibia, and humerus are the
most commonly aﬀected sites. Making the diagnosis of
OM on clinical grounds in SCD is extremely diﬃcult as
the signs and symptoms of OM mimic those of an acute
sickle vaso-occlusive episode or bone infarct. Acute long
bone infarcts are however fifty times more common than
bacterial OM in SCD [262]. It is important to make the
distinction between sickle vaso-occlusion and OM to prevent
progressive bone and joint damage with treatment delays
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and to avoid unnecessary exposure to a prolonged course
(six weeks) of antibiotic therapy. Pain, swelling, and fever
may be associated with elevated white blood cell counts
and inflammatory markers such as CRP [263]. The utility
of blood, bone, and joint aspirate cultures is limited since
most patients would have received antibiotics within the first
twenty-four hours following a febrile episode. The presence
of sterile white blood cell collections in bone and joint
aspirates is enough to confirm diagnosis.
Early changes on plan radiography are nonspecific and
include periosteal reactions, osteopenia, and lucent areas
within bone. Ultrasonography is a rapid noninvasive way of
showing extra osseous pathology associated with OM; how-
ever it has only 74% sensitivity, and findings are nonspecific
[264, 265]. Computer tomography may show subperiosteal
fluid collections with deeper collections correlating more
with presence of infection [266, 267]. The use of radio-
labeled isotopes and tagged leukocyte scans is less frequent
as false negatives and positives occur frequently. Magnetic
resonance imaging (MRI) with gadolinium enhancement
increases the sensitivity of diagnosis; however there is still
overlap between the changes seen with infection and infarc-
tion. The final diagnosis of OM is usually made using a com-
bination of clinical, radiographic, and laboratory parameters
coupled with a high index of suspicion. Sometimes surgical
aspiration is needed to drain a localized fluid collection in
subjects with poor response to antibiotics [146, 268, 269].
Septic arthritis (SA) is estimated to occur in 0.2 to
5.4% of individuals with SCD and usually occurs in an
osteonecrotic joint and is caused by similar organisms to OM
[270–272]. Septic arthritis is also a common complication
following hip arthroplasty in SCD and a reason for joint
failure. Concurrent involvement of multiple joints is not
uncommon. The diagnosis of septic arthritis also requires
a high index of suspicion. The presence of pain, swelling,
and immobility around a joint is usually assumed to be from
a typical vaso-occlusive episode. Persistence of symptoms
of pain and swelling with or without fevers should prompt
imaging studies and further laboratory workup. Serum CRP
should be obtained and if elevated should raise suspicion
for septic arthritis. The CRP is typically the first marker to
be elevated and the first to respond to treatment. Delayed
diagnosis is associated with rapid joint deterioration and
collapse [146].
The mainstay of treatment for both OM and OA is a pro-
longed course of antibiotics. Initial use of parenteral antibi-
otics against salmonella, staph, and enteric gram-negative
organisms is prudent to achieve rapid bactericidal blood
levels. A six-week course of antibiotics is recommended for
confirmed cases. Physical therapy to improve joint function
and avoid muscle wasting should be encouraged once pain
improves.
5. Neurological Complications
5.1. Ischemic Stroke. Data from the Cooperative Study of
Sickle Cell Disease (CSSCD) revealed that stroke occurred
in 11% of children with hemoglobin SS (HbSS) below
the age of 20 years and 24% of adults by age 45 [273].
However, the use of transcranial Doppler ultrasonography
(TCD) in the past two decades to identify persons at high
risk for ischemic stroke and the prophylactic management
of those patients with chronic transfusion has dramatically
reduced the incidence of childhood stroke to approximately
2-3% [274–276]; this is discussed further below. Consistent
with previous CSSCD findings, a recent retrospective study
confirmed that high systolic blood pressure, leukocytosis,
and severe anemia were correlated with MRI-documented
brain injury in children with sickle cell anemia [277]. Seizure,
sensory, and motor events were associated with the highest
risk for brain injury, while the less specific problems of
headache and poor school performance were not correlated
with increased risk. Similarly, acute CNS events in children
with sickle cell disease were associated with older age, history
of stroke, transient ischemic attack, or seizure, neurologic
symptoms, focal neurologic exam findings, and an elevated
platelet count [278].
The acute management of overt stroke has not changed
substantially in the past three decades. Patients presenting
with clinical evidence of acute cerebral ischemia receive an
immediate CT scan of the brain to rule out intracranial
hemorrhage and are initially managed in an ICU where they
receive simple or exchange transfusion to lower circulating
HbS levels to ≤30% and correct anemia to a hemoglobin
level of approximately 11 g/dL. Subsequent management
requires chronic simple transfusion or erythrocytapheresis
to maintain HbS at ≤30% (or a community standard level
of ≤45% [279]). Of major clinical benefit has been the
availability of the oral iron chelator deferasirox, which in the
United States has almost completely replaced subcutaneous
infusion of desferrioxamine as an eﬀective means of con-
trolling the burden of iron overload from chronic erythro-
cyte transfusion [280]. However, approximately 15–20% of
patients who receive chronic transfusion for secondary stroke
prevention will experience additional CVAs [281, 282]. A
more recent study reported recurrent cerebral infarcts, both
overt and silent, in 45% of children receiving chronic blood
transfusion therapy for secondary stroke prevention [283].
Moreover, many adult patients and their providers choose
to discontinue transfusion given its associated morbidities,
including alloimmunization, iron overload, and infection
[284, 285]. The multicenter randomized SWiTCH trial
compared the administration of hydroxyurea plus phle-
botomy with standard management (chronic transfusion
plus iron chelation) for the prevention of secondary stroke
and iron overload in patients who had experienced an initial
CVA (clinicaltrials.gov #NCT00122980) [286]. However, this
recently completed trial did not show equivalency of the
“experimental” regimen with standard management.
In contrast, primary prevention of ischemic stroke using
TCD screening and prophylactic chronic transfusion of per-
sons at high risk for stroke indicated by abnormal velocities
(>200 cm/sec) has dramatically lowered the overall incidence
of stroke [274–276, 287]. In most large sickle cell centers
more patients currently receive chronic transfusion for
primary stroke prophylaxis than for secondary prevention.
The STOP-II study determined that regular transfusions
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for primary stroke prevention could not be stopped safely,
even in patients with a normal MRA whose TCD studies
had normalized [288]. Within one year after stopping,
about half the children had been restarted on transfusion,
either because of stroke or stroke risk, or other indications
such as recurrent pain or severe acute chest syndrome.
While the necessary duration of transfusion remains to be
determined, STOP II indicated ongoing risk in most cases
even after prolonged transfusion, arguing for the need for
continued treatment. Thus, an important question is the
potential role of hydroxyurea in primary stroke prevention.
Early findings from nonrandomized clinical series suggested
that hydroxyurea might be an alternative to transfusion
for primary stroke prevention because of its eﬃcacy in
decreasing TCD velocity [289–291] and reducing the overall
occurrence of CNS events [287]. The recently initiated
multicenter TCD With Transfusions Changing to Hydrox-
yurea (TWiTCH) trial (a phase III noninferiority study
comparing regular transfusion to hydroxyurea in children
with abnormal transcranial Doppler studies to prevent
stroke) involves the randomization to hydroxyurea treatment
or continuation of standard transfusion to determine the
eﬃcacy of hydroxyurea in primary stroke prevention.
5.2. Silent Cerebral Infarction. Silent infarcts occur in
approximately 20% of children with sickle cell anemia and
are associated with significant compromise of neurocognitive
performance as well as an increased risk for subsequent overt
stroke [292, 293]. Children with SCA and MRI confirmed
that silent infarcts have lower intelligence quotients (IQs)
than those with a normal MRI [294]. The international
multicenter randomized silent infarct/transfusion (SIT) trial
is addressing the utility of chronic transfusion compared
with standard observation in preventing the deleterious
eﬀects of silent infarcts on the CNS (clinicaltrials.gov#
NCT00072761). Recent data indicate that silent cerebral
infarcts occur despite regular blood transfusion for sec-
ondary stroke prevention in children with sickle cell anemia
[283]. However, there is suggestive evidence that hydrox-
yureamay prevent or reduce the progression of silent cerebral
infarcts [295]. In general hematopoietic stem cell transplant
has been eﬀective in preventing reoccurrence of CNS events
[296], although progressive brain parenchymal damage has
been reported following transplant [297].
5.3. Neurocognitive Impairment. Although neurocognitive
deficits are usually associated with overt stroke in sickle
cell disease, compromise is almost as significant in persons
with silent infarcts and also occurs in those who have no
apparent lesions on cerebral MRI [294, 298, 299]. Evidence
of impairment occurs in the areas of attention, executive
function, visio-motor function, verbal performance, and
memory [299, 300]. Adults with HbSS were recently found
to have lower performance IQ scores, associated with the
severity of their anemia and increasing age [301]. In this
study 138 adults with sickle cell anemia and 37 controls were
evaluated with a battery of cognitive tests; neurocognitive
dysfunction, undetected brain injury, or both aﬀected most
of the sickle cell subjects. Areas of executive functioning,
reading, and mathematical ability were particularly aﬀected.
Sixty-three percent of sickle cell subjects had neuropsy-
chological dysfunction or abnormal findings on MRI, 38%
had neuroimaging abnormalities, including silent infarcts
and hippocampal atrophy, and 32% scored below 86 on
the Wechsler Adult Intelligence Scale (WAIS) IQ scale. In
contrast, 15% of the normal adult population scored below
86 on the WAIS scale. After controlling for age, gender, and
education, sickle cell patients performed significantly worse
than controls on the WAIS Processing Speed Index score
and the Woodcock-Johnson score, tests of reading, math,
and ability to follow directions. In addition, subtest scores of
the Test of Everyday Attention, which measures flexibility of
thought and attention, were significantly decreased in sickle
cell patients, particularly related to age. Volumetric MRI
measurements showed no significant diﬀerences in total gray
matter or volume of the hippocampus between patients and
controls, but there was a nonsignificant reduction in brain
volume with older age among adults with sickle cell anemia.
Although lacunae were more frequent in these patients, the
lesions were not related to neurocognitive function. The
results of this study suggested that standardized and com-
prehensive neuropsychological assessment may be valuable
in the management of adult patients with sickle cell disease.
Recently, diﬀusion-weighted imaging (DWI) MRI data have
been analyzed retrospectively to quantitate changes in tissue
integrity that are present in normal-appearing white matter
[302]. Subtle changes in white matter structure were related
to processing speed, suggesting that modifications in tissue
integrity may be used to predict cognitive morbidity of sickle
cell patients.
Cerebral blood flow (CBF) has also been shown to
influence neurocognitive function. Children with sickle cell
anemia and abnormal CBF velocity, measured by TCD, per-
formmore poorly on tests of verbal intelligence and executive
function [303]. Cerebral blood flow velocity has been related
to language functioning in children with SCD, particularly
in the domain involving syntactical ability [304]. The results
of this study underscore the need for neuropsychological
assessment when abnormal flow velocities are detected by
screening TCD. Examination of the relationship between
CBF and neurocognitive function in children with sickle
cell anemia (and a normal TCD) showed that CBF inversely
correlated with both full-scale and performance IQ [305].
The authors concluded that assessment of increased CBF
by continuous arterial spin-labeling MRI may allow inter-
ventions to modify the risk of neurocognitive impairment
from sickle cell anemia, potentially before silent infarcts or
abnormal CBF velocity develop.
No treatment has been demonstrated to improve
neurocognitive dysfunction in this population, but results
of a multicenter controlled randomized trial of short-
term (6-month) transfusion intervention are pending
(clinicaltrials.gov#NCT00850018). In addition, there is
suggestive evidence from a report of 15 children treated
with hydroxyurea, who scored higher on tests of verbal
comprehension, fluid reasoning, and general cognitive
ability than children not on the drug [306]. Benefit might
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ensue from lessened anemia, improving oxygen supply
to the brain, and reduced fatigue due to illness. More
definitive evidence of the eﬀects of chronic transfusion and
hydroxyurea on neurocognitive performance is expected
from the SIT trial and long-term followup of the BABY
HUG population. Interventions targeting specific areas of
neurocognitive dysfunction (such as memory) have had
some success but have been very limited in scope [307].
5.4. Moya-Moya. Moya-moya syndrome has been increas-
ingly recognized following stroke in children with sickle
cell anemia and has been associated with intellectual
decline, particularly in performance IQ [308], as well as
a markedly increased risk for subsequent cerebrovascular
event (stroke or transient ischemic attack (TIA)) [309].
Management of this complication has ranged from con-
tinuation of chronic transfusion (for secondary stroke pre-
vention) to a variety of neurosurgical direct and indirect
revascularization techniques. Two recent series have been
reported, each involving 12 patients with sickle cell anemia,
previous stroke and/or TIA, and the presence of moya-
moya syndrome despite chronic transfusion management
[310, 311]. The total of 24 patients underwent unilateral
or bilateral encephaloduroarteriosynangiosis (EDAS)/pial
synangiosis at an average age of 11-12 years and had
a mean followup of approximately four years. Except
for two subjects who had relatively limited CVAs within
three weeks of neurosurgery, the patients remained stroke-
free during their followup and were neurologically stable
or improved, indicating that this intervention should be
strongly considered for this very high risk subpopula-
tion.
6. Ophthalmologic Complications
Vaso-occlusion can aﬀect any vascular bed in the eye,
including the conjunctiva, anterior segment, retina, choroid,
or optic nerve with potentially blinding consequences [312].
Little is known about the role of genetic and environmental
modifiers in the ocular manifestations of the sickle cell
disease (SCD).
6.1. Orbital Involvement. Although rare, orbital compression
syndrome (OCS) has been reported as an ocular mani-
festation of sickle cell disease [313–315]. In a series of
3 cases, sphenoid bone infarction led to a subperiosteal
hematoma and an inflammatory response that resulted in
acute proptosis, periorbital pain, restricted motility, and
compressive optic neuropathy, known as the orbital com-
pression syndrome (OCS) [316]. OCS is often diagnosed by
magnetic resonance imaging (MRI), and most cases resolve
with medical management without the need for surgical
intervention. Timely treatment with corticosteroids may
be helpful in relieving the orbital pressure caused by the
inflammation and reversing the associated optic neuropathy.
Antibiotic coverage is also recommended if a coexisting
infection is suspected or cannot be excluded. In cases with
failed response to medical management, surgical drainage
of the subperiosteal collection is indicated urgently [313–
315].
6.2. Conjunctiva. One of the early vaso-occlusive features in
SCD may be seen in the conjunctival vasculature. Abnor-
malities take the form of transient saccular and sausage-
like dilations packed with red cells, resulting in dark red,
comma-shaped vessel segments, most notably in the inferior
bulbar conjunctiva [317]. Paton reported that these comma
signs were more common in SS than in SC disease and were
uncommon in patients with high HbF levels. The results
of a study investigating the influence of clinical, laboratory,
and genetic features on conjunctival and retinal vessel
alterations indicated that low levels of Hb and hematocrit
may be risk factors for conjunctival alterations. Conjunctival
abnormalities were more evident in patients with SS disease
[318].
Conjunctival blood flow improves following transfusion.
The comma signs are also noted to diminish under heat from
slit lamp beam illumination, which probably induces vasodi-
lation. Abnormalities increase with pharmacologic agents
inducing vasoconstriction, and these eﬀects are reported to
be more apparent in the pediatric patient group [319, 320].
Histopathologic examination of these conjunctival vessels
demonstrated endothelial proliferation, aggregation of red
blood cells in the distal portion of capillaries, and dilatation
and thinning of the proximal segments of the vessels [321].
Visual acuity is not aﬀected. The “comma sign” vessels in
conjunctiva are an excellent diagnostic tool for sickle cell
disease, but they are absent in sickle cell trait.
6.3. Anterior Chamber. The anterior chamber of the eye,
normally filled with aqueous humor, has low oxygen tension,
low pH, and high ascorbate concentration (a reducing agent)
and may be filled with red blood cells following trauma or
surgery, resulting in a condition called hyphema. When ery-
throcytes and leukocytes consume oxygen and liberate CO2
and lactic acid leading to acidosis, even sickle trait red cells
become sickled. They then become trapped, since deformed
and less pliable sickle cells are unable to pass through the
0.3–2 μm pores of the aqueous outflow apparatus, namely,
the trabecular meshwork and intraocular pressure increases
[322, 323]. Only a moderate increase in intraocular pressure
may cause a reduction in perfusion of the optic nerve head
and retina, and an increased risk for optic atrophy and
retinal artery occlusion, resulting in irreversible vision loss
[324]. The presence of blood in the anterior chamber should
be considered an emergency and should prompt an eye
examination, including intraocular pressure measurement.
Intraocular pressure should be around 25mmHg or less
[325, 326]. Anterior chamber paracentesis and intracam-
eral injection of tissue plasminogen activator (t-PA) were
reported to successfully normalize pressure and the vision
in a child with posttraumatic hyphema, thrombosis in
the trabecular meshwork and consecutive acute, secondary
glaucoma [327]. Paracentesis by itself is often suﬃcient.
Transcorneal oxygen therapy may also reduce the intraocular
pressure in patients with glaucoma induced by sickle cell
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Figure 1: (A) Ultrawide field fundus photograph of the right eye shows a black sunburst lesion (arrow), a flat, round, black patch along the
superior arcade temporally. (B) Ultrawide field fluorescein angiogram of the right eye in the arteriovenous phase demonstrates the staining
of the sunburst lesion (arrow).
hyphema [328], by converting rigid erythrocytes to pliable
ones, which can then escape from the eye through the
trabecular meshwork.
6.4. Posterior Segment Manifestations. Posterior segment
findings include retinal hemorrhages and exudates, angioid
streaks, chorioretinal infarctions, vitreous hemorrhage, cen-
tral or branch retinal artery occlusion, and proliferative sickle
cell retinopathy (PSR).
6.4.1. Salmon Patch Hemorrhage. Salmon patch hemorrhage
represents a well-defined area of hemorrhage located within
the superficial retina, between the sensory retina and its
internal limiting membrane. It usually occurs in the mid-
peripheral retina adjacent to an intermediate-sized arteriole
[312]. Although the hemorrhage is initially bright red, it
may turn salmon-colored over time because of progressive
hemolysis, and resorption may result in a retinoschisis
cavity. If the retinoschisis cavity contains refractile, copper-
colored granules, it is called an iridescent spot. Histologi-
cally, these deposits contain hemosiderin-ladenmacrophages
[329, 330].
6.4.2. Black Sunburst. Intraretinal hemorrhages may track
into the subretinal space, dissecting between the neurosen-
sory retina and the retinal pigment epithelium (RPE),
resulting in RPE migration into the site and forming the
stellate and spiculate hyperpigmented lesion known as a
black sunburst. The black sunburst lesion appears as a flat,
round-to-oval, black patch about 0.5–2mm in size (Figures
1(a) and 1(b)). Glistening refractile granules, similar to those
in iridescent spots, may be present [312]. A large amount
of intraretinal and subretinal hemorrhage may rarely alter
the extracellular matrix or fibrous component of Bruch’s
membrane, allowing development of spontaneous choroidal
neovascularization growing within the black sunburst lesion
[331].
6.4.3. Vasoocclusions. Vaso-occlusions may occur in the
retina or less commonly in the choroid of patients with sickle
cell disease. In the retina, the initial vaso-occlusions typically
occur in the peripheral retinal vasculature andmainly involve
capillaries and precapillary arterioles. In more advanced
retinopathy, occlusions can occur in any vessel within the
peripheral retinal vasculature and can result in new vascular
formations characteristic of sickle cell disease, such as sea fan
neovascularization and hairpin loops [332] (Figures 2(a)–
2(c), and 5(d)). Occlusion of major branch retinal arteries
and even the central retinal artery may occur. One study
reported that arteriovenous crossings were common sites
of sea fan formation [333]. This same study demonstrated
that these neovascular formations were very complex in
that they can have multiple feeding arterioles from the
retina and multiple draining venules [333]. Sea fans often
autoinfarct, leaving white, fibrous tissue remnants adherent
to the cortical vitreous (Figure 3).
Several case reports suggest that vascular occlusions
also occur in the choroid [334, 335]. Choroidal nonper-
fusion is thought to result from occlusive events in the
posterior ciliary arterial circulation. It was hypothesized
that these occlusions may also be the stimulus for forma-
tion of choroidal neovascularization (CNV) and that this
neovascularization may be involved in formation of some
pigmented lesions, including some black sunburst lesions
[332].
6.4.4. Angioid Streaks. Angioid streaks are small breaks in
Bruch’s membrane, which separates retina from choroid.
Angioid streaks resemble blood vessels, thus their name, and
typically emanate radially from the optic nerve. These streaks
are thought to be due to calcification and fragility of Bruch’s
membrane [312]. They are particularly common in the SS
genotype.
6.4.5. Macular Findings. The macular findings in patients
with sickle cell disease include abnormal perfusion and
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Figure 2: (A) Fundus photograph of new vascular formations characteristic of sickle cell disease called sea fan formations (arrow), which
tend to occur in the temporal periphery. (B) Fluorescein angiogram in the arteriovenous phase shows peripheral nonperfusion and sea
fan neovascularization at the border of vascularized and nonvascularized retina (arrow indicates the largest sea fan). (C) Late phase of the
angiogram shows fluorescein leakage from sea fans as the dye study progresses.
Figure 3: Color fundus photo shows a white autoinfarcted sea fan
in the midperipheral retina with white, fibrous tissue remnants
adherent to the cortical vitreous (top). Also note white, occluded
retinal vessels.
an enlarged foveal avascular zone (FAZ) due to vaso-
occlusive episodes. Epiretinal membranes, schisis, holes, and
neovascularization may also occur. The “retinal depression
sign” was first described by Goldbaum as an abnormality in
the reflection from the internal limiting membrane due to
depression of the inner surface resulting from a small retinal
infarct and subsequent atrophy [336]. These changes can
now be demonstrated using noninvasive imaging techniques,
such as optical coherence tomography (OCT), which oﬀers
high-resolution, cross-sectional images that correlate with
the histological features in patients with retinal diseases.
OCT enables visualization of tissue structures up to 2mm
below the surface [337]. The imaging is analogous to B-
mode ultrasonography except that light instead of sound is
used in this technique. Reversal of precapillary occlusions in
the perimacular region may occur spontaneously; however,
loss of the inner layers of the retina results in the retinal
depression sign. Thinning of the temporal inner macula,
presumably caused by ischemia and eventual atrophy of
retinal ganglion cells and the nerve fiber layer, has also been
shown with OCT [338, 339] (Figures 4(a) and 4(b)).
The presence of multifocal perifoveal occlusions was sug-
gested to result possibly from a central retinal artery occlu-
sion with migration of microemboli downstream in a 9-year-
old boy with SS hemoglobinopathy [340]. In the presence
of macular occlusive changes, emergency methods, such as
anterior chamber paracentesis to lower the intraocular pres-
sure, may be indicated in an attempt to prevent infarction
and irreversible vision loss [341]. Additionally, immediate
or regular exchange erythrocyte transfusions are sometimes
used to improve visual outcomes or to prevent vision loss in
the fellow eye. Evidence for eﬃcacy is presently lacking.
Fluorescein angiography and automated perimetry of the
central 30 degrees are more sensitive tests for detection of
ischemic macular disease than visual acuity, and macular
ischemia can be quantified by these two techniques [342].
Since many of the macular changes seen in sickle cell disease
are subtle and can be missed by ophthalmoscopy, thorough
evaluation, including angiography, OCT, and perimetry, is
often important in the diagnosis and management of these
patients.
Although infrequent, macular holes can also be seen
in association with proliferative sickle cell retinopathy. The
occurrence of fibroglial proliferation around the disc, with
subsequent nasal traction on the macula, along with tempo-
ral traction resulting from vasoproliferative tissues near the
temporal equator, has been suggested to play an important
role in the formation of macular holes by stretching of
the retina. The occlusion of perifoveal capillaries may
be another possible mechanism, because it causes retinal
atrophy, thinning, and possible hole formation [343].
6.4.6. Retinoschisis. Retinoschisis is a rare complication of
sickle cell retinopathy that is related to chronic low-grade
ischemia of the inner nuclear layer [329]. It is characterized
by a concave retinal elevation, inner-layer breaks, and a split
pattern on OCT. Additional breaks in outer layers may com-
plicate the course of the disease and result in retinal detach-
ment in such cases [344]. Timely laser treatment may reduce
the rate of full thickness retinal detachment in these patients.
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Figure 4: (a) Optical coherence tomography image of the right eye with a cross-section of the macula that demonstrates thinning of the
inner layers (arrows), in the temporal aspect of the macula, whereas the nasal side of the macula (right) is normal in thickness. Thickness
map below demonstrates the area of thinning, outlined by the blue color and shown by the arrow. (b) Optical coherence tomography image
of the left eye shows a cross-section of the macula that demonstrates thinning of the inner layers, as indicated by the arrows, in the temporal
aspect of the macula. Thickness map below demonstrates the two areas of thinning outlined by the blue color and shown by the arrows.
6.4.7. Disc Sign. The disc sign in sickling hemoglobinop-
athies is the appearance of isolated comma or hyphen-
shaped small vascular segments on the surface of the
optic nerve head. It is most likely due to piling up and
subsequent deoxygenation of sickled erythrocytes caught at
bifurcations in the capillary bed or precapillary arterioles
and is most commonly seen in patients with HbSS disease.
These transient plugs do not seem to result in any visual
changes or loss [345]. They are analogous to, and resemble,
the conjunctival comma sign.
6.4.8. Proliferative Sickle Retinopathy (PSR). Arteriolar
occlusion and loss of capillary perfusion in the peripheral
retina are the most striking features of sickle cell retinopa-
thy. They are generally more prominent in the temporal
peripheral retina, especially superotemporally. The ischemic
areas caused by these occlusions release substances that can
stimulate angiogenesis [346]. The initial vascular remodeling
at the junction between the perfused central and nonper-
fused peripheral retina includes the creation of arteriovenous
(AV) anastomoses and hairpin loops [347] (Figures 5(a)–
5(d)). Proliferative retinopathy occurs most frequently in
HbSC disease with an incidence of approximately 33%.
The condition is much less common in patients with
Sβ-thalassemia; about 14% of patients with this genotype
have PSR [346]. PSR can also be seen in patients with HbSS
disease, though less commonly [348]. The peak prevalence of
PSR in the HbSC genotype occurs earlier than in the SS type
(about 15–24 years inmen and 20–39 years in women) [349].
Table 2: Staging of proliferative sickle retinopathy.
Clinical findings
Stage I Peripheral arteriolar occlusions
Stage II
Vascular remodeling, formation of arteriovenous
anastomoses
Stage III Peripheral retinal neovascularization
Stage IV Vitreous hemorrhage
Stage V Retinal detachment
Goldberg and colleagues developed a widely accepted
grading system detailing the stages of proliferative sickle
retinopathy (Table 2) [320, 350].
Recent studies investigating the pathogenesis of retinal
angiogenesis have focused on the balance between pigment
epithelium-derived factor (PEDF), an anti-angiogenic fac-
tor, and vascular endothelial growth factor (VEGF), an
angiogenic factor [351]. PEDF is a multifunctional factor
that has both neurotrophic and antiangiogenic eﬀects.
In retinal ischemia, the development and progression of
neovascularization may be influenced by the change in
balance between VEGF and PEDF. It has been shown that the
abnormalities in VEGF and PEDF levels are minimal before
proliferative changes occur. The balance between PEDF and
VEGF changes as the disease progresses to the proliferative
stage. The main changes that have been observed include
a decrease of the PEDF/VEGF ratio in the feeder vessels
and active sea fan blood vessels, whereas in regression of
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Figure 5: (A and B) Color fundus photographs of both eyes show white, occluded vessels (arrows) in the periphery bilaterally. (C and D)
Ultrawide field fluorescein angiograms of the right and the left eye demonstrate the initial vascular remodeling at the junction of the perfused
central, and nonperfused peripheral retina (arrows) includes arteriovenous (AV) anastomoses (black arrow head) and hairpin loops (solid
white arrow head).
neovascularization, there was an increase in the PEDF/VEGF
ratio [352].
6.5. Treatment
6.5.1. Indications. Observations in a Jamaican cohort study
showed that spontaneous regression occurred in 32% of
eyes with PSR. Permanent vision loss was rare among the
subjects followed for 20 years until the age of 26 years [353].
Given the high rate of spontaneous regression (Figure 3)
and the lack of progression of sea fans in some eyes,
indications for treatment of retinal neovascularization have
varied among diﬀerent authors. Therapeutic intervention
is usually undertaken in cases of bilateral proliferative
disease, spontaneous hemorrhage, large elevated sea fans,
or rapid growth of the neovascular tissue or in cases in
which the fellow eye has already been lost due to PSR
[354]. If peripheral neovascularization exceeds 60◦ of the
circumference, therapy is usually implemented.
The goal is to induce regression of stage III lesions prior
to a substantial hemorrhage and/or retinal detachment. With
an early, successful treatment, the need for pars plana vitrec-
tomy and/or scleral buckling, and their associated potential
surgical complications, can be avoided [355–358]. Various
techniques, including laser photocoagulation, cryotherapy
and diathermy, have all been used to achieve involution of
neovascular lesions. Specific methods of laser application
include feeder vessel coagulation, local scatter coagulation
with or without focal treatment of the sea fan, and 360-
degree peripheral scatter delivery.
6.5.2. Laser Photocoagulation
Feeder Vessel Photocoagulation. Prior to demonstration of
the indirect eﬀect of peripheral retinal destructive therapy
on proliferating capillaries by suppression of vascular growth
factors, laser treatment was used to occlude feeding vessels.
Direct, heavy laser treatment was applied to the feeding
arterioles and then to the draining venules. The sea fans
were closed in 88% of eyes studied in a controlled clinical
trial [359]. Although both xenon arc and argon lasers have
been eﬀective in achieving sea fan closure, the argon laser is
currently more commonly used, because the risk of damage
The Scientific World Journal 19
Figure 6: (A) Ultrawide field photograph of the left eye shows the sea fans with overlying preretinal hemorrhage in the superotemporal
periphery as shown by the arrow. (B and C) Fluorescein angiogram delineates the nonperfused peripheral retina in the arteriovenous phase
with 2 sea fans that leak as the study progresses. (D) Ultrawide field fundus image of the left eye demonstrates the guided scatter laser
photocoagulation (asterisk) applied to the areas of nonperfusion noted on the fluorescein angiogram.
to Bruch’s membrane is higher with the xenon arc [312].
Short-term complications included retinal or choroidal hem-
orrhage, peripheral choroidal ischemia, macular traction,
and retinal detachment. Given the relatively high-power
settings required to close arteries and arterioles (and the
risk that such high-power laser light may damage Bruch’s
membrane), significant complications, including choroidal
and choriovitreal neovascularization, have been observed.
In a series of 53 eyes with PSR, at least 21 (39.6%) of
the treated eyes developed chorioretinal or choriovitreal
neovascularization [360]. Feeder vessel treatment is currently
used only in refractory cases with recurrent bleeding and if
scatter photocoagulation has failed.
Scatter Photocoagulation. The preferred therapy by many
clinicians is either localized or widespread scatter photo-
coagulation because of its low rate of complications. It
is performed similar to its use in proliferative diabetic
retinopathy. The goal is to destroy nonperfused retina that
is responsible for production of the angiogenic factors
initially triggered by ischemia [361]. The laser scar enhances
chorioretinal adhesion, potentially preventing or minimizing
the extent of subsequent retinal detachment.
The new Optos P200MA Ophthalmic Imaging Sys-
tem may oﬀer a distinct advantage over the traditional
angiographic imaging in evaluating patients with sickle
cell disease. The technology provides ultrawide field, high-
resolution angiography, red-free, and full-color imaging,
captured via a noncontact and nonmontage acquisition
process, with up to a 200◦ internal view of the retina at one
time. The images in Figures 1, 2, 5, and 6 were acquired
with the Optos P200MA. Visualization of the periphery and
peripheral lesions has contributed to the management and
monitoring of these patients by allowing physicians to assess
the status and progression of the disease beyond the posterior
pole [362].
The P200MA uses low-powered laser wavelengths that
scan simultaneously. While the red (633 nm) and green
(532 nm) lasers are used to image the retina and the
choroid, the blue (488 nm) laser permits the addition of
fluorescein angiography with the ability to image almost the
entire retina. Photocoagulation is now guided by findings
on the wide-field angiography and is applied to areas of
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nonperfusion noted in these images adjacent to sea fans
(Figures 6(a)–6(d)). The sea fans themselves are not focally
or directly treated unless they are completely flat and not
elevated into the vitreous chamber.
There are two retinal ablation techniques suggested for
patients with PSR: sectoral and circumferential. Sectoral
ablation is scatter photocoagulation only in the area around
neovascularization. It has shown a reduction in vitreous
hemorrhage and visual loss, without numerous complica-
tions [363]. However, in patients with vitreous traction
in association with sea fan neovascularization, argon laser
photocoagulationmay sometimes result in retinal breaks and
retinal detachment [364].
Regular followup is critical to assess progression of
neovascular disease or treatment response following local,
sectoral scatter photocoagulation. Despite scatter treatment,
new neovascular fronds may develop in up to 34% of eyes
[363].
A 360-degree peripheral scatter photocoagulation may
be considered for an unreliable patient. In one series,
peripheral circumferential retinal scatter photocoagulation
to the peripheral zones of retinal capillary nonperfusion was
shown to result in complete regression of 33% of preexisting
sea fans [365]. As yet, there is no definitive evidence
proving that the results of this approach are superior to
the natural course of untreated disease or to sector scatter
photocoagulation around individual sea fans [357, 366].
6.5.3. Transscleral Diode Laser Photocoagulation. This tech-
nique was shown to be eﬀective and safe in a case of PSR with
vitreous hemorrhage and can be considered an alternative
method in eyes when transpupillary laser application is not
possible due to clouding of the media [367].
6.5.4. Cryotherapy. For successful photocoagulation, the
media must be suﬃciently clear overlying the vasoprolifer-
ative tissue to allow the photocoagulation beam to form a
sharp image on the retina. Vitreous hemorrhage or lenticular
opacities can interfere with an adequate view of the retina
and prevent successful photocoagulation. In such cases,
the single freeze-thaw technique has been successful in
approximately 70% of treated sea fans [368]. The vitreous
traction and preexistent retinal thinning associated with PSR
make the triple freeze-thaw cryopexy technique, however
highly risky, because it may result in retinal breaks and
detachment [369].
6.5.5. Laser Vitreolysis. The neodymium: yttrium-
aluminum-garnet (Nd : YAG) laser has been used in
patients with PSR to reduce vitreoretinal traction by lysing
localized, taut vitreous bands or to clear the media in front
of the macula [370]. Safety is maximized when the bands are
avascular or only minimally perfused and are located at least
3mm from the retinal surface. Complications of posterior
segment Nd-YAG laser treatment have been previously
described and include choroidal hemorrhage, damage to
the retinal pigment epithelium, and bleeding from perfused
vascular bands [371–373].
6.5.6. Pars Plana Vitrectomy and Scleral Buckling. PSR may
cause vitreous hemorrhage that occasionally is severe or
persistent and that requires surgical intervention. Patients
with new vitreous hemorrhages may be followed for at
least 6 months to allow spontaneous clearing of the media
when there is no associated retinal detachment [354, 356].
Early surgical intervention is indicated if the hemorrhage is
associated with rhegmatogenous retinal detachment.
Full-thickness macular hole is another indication for
vitrectomy surgery in patients with PSR. The surgical
approach usually includes vitrectomy and removal of epireti-
nal membranes [374, 375].
Vitrectomy and scleral buckling surgery carry signif-
icantly higher risks of intraoperative and postoperative
complications in patients with sickle hemoglobinopathies.
There has been, however, considerable advancement of
vitreoretinal surgical techniques and instrumentation in
the course of recent years, making this type of surgery
much safer than ever before. The introduction of endolaser
photocoagulation, intraocular diathermy, endoillumination,
and, most recently, small gauge, microincisional surgery is
one of the advances that has improved the rate of surgical
success in patients with sickle cell disease.
Vitrectomy is often combined with scleral buckling in
patients with enlarged or progressive tractional detachments
or with a notable tractional component in association with
proliferative disease. The success rate, however, for visual
acuity improvement in a series of eyes with tractional retinal
detachment with or without a rhegmatogenous component,
requiring vitrectomy plus a scleral buckling procedure, was
only 50% [356]. Complications associated with vitreoretinal
surgery include iatrogenic retinal breaks, intraocular bleed-
ing, secondary glaucoma, and anterior segment ischemia. In
one series, the high incidence of iatrogenic tears and bleeding
associated with the delamination technique leads to a switch
in methodology to a segmentation technique that was per-
formed only if necessary to remove the vitreal attachments.
Scatter laser or feeder vessel treatment as an attempt to try to
induce regression of preretinal neovascularization was found
unnecessary. The authors also suggested that the vitreous
hemorrhage may be allowed to clear spontaneously without
detriment. Tractional retinal detachment was also observed
without apparent progression in some patients [376].
Anterior segment ischemia was reported to occur in 71%
of patients undergoing a scleral buckling procedure [377].
It was also reported to occur after pars plana vitrectomy
with panretinal photocoagulation without scleral buckling
[378]. The precipitating factors include significant rise in
intraocular pressure, or other causes of reduced ciliary blood
flow, caused by sickled erythrocytes.
6.6. Future Directions. Recent studies showed that the bal-
ance of PEDF and VEGF changes as the disease progresses
to the proliferative stage [352]. This was due to an elevation
of VEGF levels. Bevacizumab (Avastin) is a recombinant
humanized monoclonal IgG1 antibody that binds to and
inhibits the biologic activity of human VEGF in in vitro
and in vivo assay systems. It is approved for the systemic
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treatment of metastatic colorectal cancer. However, stud-
ies reporting oﬀ-label use of intravitreal bevacizumab in
patients with neovascular age-related macular degeneration
have shown promising results. It has also been shown
that the intravitreal injection of bevacizumab resulted in
regression of retinal neovascularization in patients with
sickle cell disease in an anecdotal report [379]. Controlled,
clinical trials are required to assess the role of anti-VEGF
agents in treatment of patients with PSR via the intravitreal
route.
Although it has been assumed that sickled erythrocytes
solely contribute to the vaso-occlusive processes seen in
sickle cell disease, there is evidence that neutrophils may
also contribute to the process [380]. The adhesion molecules
responsible for PMN rolling and firm adherence, P-selectin
and ICAM-1, have been shown to be elevated in the sickle cell
retina and in sea fan formations. Cytokines, such as tumor
necrosis factor (TNF)α and IL-1α, upregulate leukocyte
adhesion molecule expression by vascular endothelial cells
[381]. Both of these cytokines are elevated in steady-state
sickle cell subjects, probably due to a low-grade inflam-
mation caused by abnormal adhesion of sickled RBCs to
endothelial cells [382]. Several reports have also demon-
strated that some reticulocytes from sickle cell patients have
the integrin α4β1 (VLA-4) on their surface [383, 384]. The
adherence of reticulocytes via VLA-4, after administration
of TNF-α, was demonstrated in a rat model of sickle-cell-
mediated retinal vascular occlusion. Blocking VLA-4 with a
cyclic peptide or monoclonal antibody has been shown to
prevent sickled RBC retention in the retina in this model
[385]. The mechanisms for retention of SS RBCs in retina
and choroid appear identical. TNF-α stimulated retention
of the SS red cells in choroid appears to be mediated
by VLA-4, and this retention was inhibited by a VLA-4
antagonist (TBC772), a cyclic peptide, or by blocking one
of the VLA-4’s ligands, the CS-1 portion of fibronectin
[386].
Recurrent vaso-occlusion and tissue infarction cause
a repetitive inflammatory reaction in patients with sickle
cell disease (SCD). The importance of inflammation is
highlighted by observations that anti-inflammatory agents
ameliorate SCD in humans and in animal models [195, 387].
Omega-3 polyunsaturated fatty acids (docosahexaenoic
(DHA) and eicosapentaenoic (EPA) n-3 fatty acids) are
precursors of anti-inflammatory and antiaggregatory eicos-
anoids. It was shown that the red cell and platelet membrane
DHA and total n-3 fatty acids were significantly lower in
patients with sickle cell disease complications. The data sug-
gested that the reduced levels of DHA and EPA cause a greater
tendency for inflammation and organ damage in patients
with SCD [388, 389]. These findings provide insight into
the biological basis of the potential benefits of n-3 fatty acid
therapy in SCD. In a prospective, placebo-controlled, pilot
clinical trial, the mean number of vaso-occlusive crises in five
SCD patients decreased from 7.8 to 3.8 per year following
oral intake of 0.25 g/kg/day of menhaden fish oil containing
12% EPA and 18% DHA (P < 0.01) compared with pre- and
posttreatment crisis rates of 7.6 and 7.1 per year in five others
taking the same doses of olive oil as placebo (P > 0.4) [390].
Recent studies have, therefore, shed light onto the
pathogenesis of SCD and may permit identification of new
treatment modalities in these patients.
7. Pediatric Pain Syndromes:
Pathophysiology, Assessment,
and Management of Pain in Children from
Infancy through Adolescence
7.1. Infants and Young Children. Many early studies of SCD
in infants and young children concentrated on the initial
manifestations of SCD that might be a hint to early diagnosis
of this disorder, while subsequent studies after the advent
of newborn screening have focused on factors associated
with specific clinical events, such as pain, which did not
suﬀer the ascertainment bias that was common in early
studies. Bainbridge et al. described the experience from
Jamaica of 314 children with SS identified over an 8-year
period from 6/73–12/81 [391]. Occurrences of clinical events
were recorded retrospectively from information obtained
at scheduled clinic visits. No specific sickle cell-related
symptoms were recorded prior to 3 months of age, and only
16 (6%) infants had such symptoms prior to 6 months of
age. Of these initial symptoms prior to 6 months, 50% were
episodes of dactylitis, which was similar in frequency to those
over the first 2 years of life. After 2 years of life dactylitis
became less common, and more generalized painful episodes
predominated. The same patient cohort (233 children from
6/73–8/79) had been used previously tomore closely describe
the dactylitis episodes [392]. The frequency of episodes was
relatively constant between 3 and 15 months and accounted
for about half of the dactylitis episodes in the first 5 years of
life in SS patients. There was no gender diﬀerence in dactylitis
frequency. The level of fetal hemoglobin was significantly
lower, and the reticulocyte count was significantly higher at
6 months of age in those children with dactylitis, but these
diﬀerences were no longer significant at 24 months of age.
Factors that predict the incidence of dactylitis and painful
episodes have also been analyzed using survival curve meth-
ods and proportional hazards regression in the Jamaican
newborn cohort data [393] concentrating on the age to first
occurrence. Patients were grouped into one of three equal
groups based on their fetal hemoglobin level at age 5 years,
which was similar in rank to fetal hemoglobin levels from
6 months, 2 years, or 10 years of age instead. The trend
in occurrence of dactylitis by fetal hemoglobin grouping
was highly significant for male, but not female SS children.
However, the low fetal hemoglobin group for both males and
females had a significantly earlier onset of dactylitis. Similar
relationships were seen for painful episodes.
Gill et al. reported the experience of the Cooperative
Study of Sickle Cell Disease (CSSCD) which enrolled 694
infants identified with SCD by newborn screening prior
to 6 months of age and followed them prospectively up
to age 10 years, from 10/78 to 10/88 [394]. Dactylitis
resulting in a hospital-based encounter (clinic, ER, or in-
patient service) had a peak incidence during the 6–12-month
period and was rarely seen after 3 years of age. In contrast,
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painful episodes not involving the hands and feet were
rare in the first year of life and became progressively more
common thereafter. Dactylitis was extremely uncommon in
SC patients, and painful episodes ranged from about 1/3
to 2/3rd as common as similarly aged SS patients. Overall
pain rates were estimated at 0.3 episodes per patient per year
[395].
7.2. School-Aged and Adolescents. The most comprehensive
study of pain frequency in this age group comes from the
Cooperative Study of Sickle Cell Disease (CSSCD), which
examined a 10-year longitudinal cohort of about 4000 adults
and children [395]. Rates of hospital-treated pain averaged
in the 5–19 between 0.5 and 1.0 episodes per patient-
year. However, there was considerable interpatient variability
as 46% of the patients with Sickle Cell Anemia aged 0–
9 years, and 32% aged 10–19 years had no episodes in a
given year, while 7% of the patients aged 10–19 years had
between 3 and 10 hospital visits for pain treatment each
year. This latter group of patients accounted for a substantial
proportion of all hospital-treated episodes. Higher pain rates
were associated with higher hematocrit levels and lower
fetal hemoglobin levels on multivariate regression. Similar
relationships between pain frequency and hemoglobin levels,
fetal hemoglobin levels, and measures of sickle cell adhesion
have also been documented in school-aged children and
adolescents in the home setting [396]. Recent studies have
also suggested a role for the influence of inflammatory
mediators in the frequency of vaso-occlusive pain frequency
[397, 398].
Health-related quality of life and its relationship to pain
have been studied QOL using the PedsQL version 4.0 generic
core and fatigue scales in 1772 subjects (53% boys) with a
mean age of 9.6 years (SD 4.7) from the Collaborative Data
(C-Data) Project of the Comprehensive Sickle Cell Centers
(CSCC) Clinical Trial Consortium [399]. Multiple regression
models controlling for hemoglobinopathies, gender, and age
showed that parent reports of physical functioning and
sleep/rest fatigue declined in response to the occurrence of
pain or avascular necrosis, while school functioning scales
declined in response to pain or asthma. Sickle pain, and to
a lesser extent asthma, negatively influenced child reports on
almost all functioning and fatigue scales. These and other
epidemiologic studies of sickle continue to help us under-
stand the variability of the sickle pain experience. Future
studies are necessary to understand the frequent transition
from acute recurrent pain in childhood to persistent pain in
adults with SCD [400].
7.3. Assessment. A substantial literature exists that describes
pain characteristics in school-age children (>6 years) and
adolescents, and recommendations have been made for
appropriate pediatric assessment instruments [401, 402].
Pain intensity assessment in children and adolescents with
SCD is similar to other pediatric populations and has
largely relied on traditional self-report measures (e.g., visual
analogue scales, categorical scales, etc.). Pain assessment in
young children becomes increasingly problematic as their
cognitive understanding limits their ability to discriminate
relative sizes or line lengths or abstract concepts of pain and
its causation. Ultimately, self-report fails in children under
3-4 years of age; behavioral observations have been used as
alternative measures [403], as has parent-proxy reporting
[404].
Initial studies of hospitalized children and adolescents
with sickle pain examined 17 adolescent and young adult
patients who were hospitalized for treatment of severe pain
with parenteral morphine using the Varni-Thompson PPQ
[405]. Pain intensity was very high in the first several
days of hospitalization (8-9/10) and progressively decreased
during the remainder of the hospital stays (P < .0001, by
ANOVA with hospital day as independent variable and VAS
as dependent variable). A similar temporal trend for pain
relief was also seen, with generally very poor pain relief early
in the painful episode and good pain relief by the time of
discharge. Patients reported a mean of 3 ± 2 (mean ± SD)
painful sites on day 1 of hospitalization, with spine, sternum,
both knees, and both ankles being the four most common
sites. Subsequent studies have documented similar findings
[406, 407].
A number of studies have described the characteristics
of vaso-occlusive pain in the home setting [396, 408]. In
a study of 39 children and adolescents followed with daily
diaries [396], the number of pain episodes reported in
the 6-month study period varied widely between patients
(range 0–31 episodes). Patients with at least one episode
a month represented 40% of the study participants, while
12% had more than 2 episodes per month. The frequency
of painful episodes managed at home was highly variable
among patients and did not vary significantly by gender,
age, or hemoglobinopathy. Most episodes were relatively
brief with 59% of episodes in younger children (5–9 years)
and 46% in older children lasting one day or less. On
multivariate analysis, older age (10–19 years), female gender,
and SCD-SS genotype were associated with significantly
longer episode durations. Episodes of one day or less were
much more common in individuals with SCD-SC genotype
(67%) compared to those with SCD-SS (40%).
Vaso-occlusive pain experienced during these episodes
was of mild-to-moderate intensity on the majority of
reported days with pain, but severe pain, rated as 7 or higher
on a 10-point intensity scale, was reported on 12% of days.
Gender or hemoglobinopathy did not significantly influence
pain intensity, while younger children on average reported
less intense pain than did older children. Pain was localized
to one or two distinct sites on 65% days with vaso-occlusive
pain. While age and hemoglobinopathy did not influence the
number of sites, female gender was associated with a higher
number of reported painful sites.
A number of personal factors can also contribute to the
sickle pain experience. For example, a study of adolescents
with SCD (n = 37; aged 13 to 17 years), who completed daily
diaries assessing pain, stress, mood, activity, and health-care
use for up to 6 months, showed that daily increases in stress
and negative mood were associated with increases in same-
day pain, health-care use, and reductions in school and social
activity usingmultilevel regressionmodeling [409]. Increases
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in positive mood were associated with decreases in pain,
less health-care use, and more activity participation. Similar
studies suggest that optimism is a significant moderator
of the relation between pain and opioid-medication use in
adolescents [410]. At medium and high levels of optimism,
pain was positively related to opioid use, but at low levels
of optimism, the same relation was not present, suggesting
that more optimistic adolescents are better able to match
their medication use to their pain severity. Self-esteem of
adolescents with SCD has also been correlated with less
depression and anxiety, while a sense of inadequacy has been
associated with poorer functioning [411]. Current and future
research is examining how other psychosocial factors might
influence pain severity or medication use in adolescents who
experience pain. Determining how resilience factors protect
adolescents with SCD may aid in the development of future
psychosocial interventions and help clinicians understand
how to take into account psychosocial factors when working
with pain patients.
Another evolving area of pain assessment is the develop-
ment of assessment tools to characterize the impact of pain
on daily activities. The NIH-sponsored Patient Reported
Outcomes Measurement Information System (PROMIS) has
developed validated pediatric assessment tools for a number
of relevant domains including physical functioning and
pain interference [412]. Other investigators have developed
measures that characterize the ability to perform specific
common physical activities that may be impaired by pain
[413, 414]. Novel technologies are also being developed
to provide objective measures of physical activities [415]
that may be useful in characterizing the consequences of
pain. These assessments may help guide both research and
therapies for acute or persistent pain.
7.4. Management. Pain management in children with SCD
presents unique challenges and opportunities. A recurrent
pain condition with unpredictable occurrence and severity
with variable response to pharmacologic therapies represents
the fundamental challenge. The opportunity aﬀorded by
SCD is to provide anticipatory and concurrent guidance to
children and their families while the child is asymptomatic
to encourage and support the use of a variety of cognitive-
behavioral therapies, positive coping skills, and an accep-
tance of lifelong pain disorder.
Pharmacologic therapies for acute pain in childhood are
similar to that of other acute pain disorders in children.
Much of the pain experienced and treated at home is of mild-
to-moderate intensity and responses well to acetaminophen
or nonsteroidal anti-inflammatory agents (NSAIDs) [416],
while more severe acute pain often responds to some degree
to a combination of NSAIDs and oral opioids. When
adjusted for body weight or size, the pharmacology of
commonly used opioids, such as oxycodone, in children
older than 6–12 months of age is similar to adolescents
or adults [417]. A variety of cognitive-behavioral therapies
are likely eﬀective adjunctive therapies for all acute pain
[418, 419]. Physical therapies such as heat and massage are
also commonly used by children and their families for sickle
cell pain [416, 420] and likely eﬀective [421, 422].
Management of severe vaso-occlusive pain in the acute
care or hospital setting is somewhat more problematic.
Parenteral opioids given on a time-contingent basis, often in
combination with parenteral NSAIDs, is the most common
pharmacologic therapy in this situation, but few large
controlled trials are available to guide dosing. Frequent dose
titration to adequate pain relief in specialized day hospital
units has been quite eﬀective in children [423], as it has
been in adults, but has been diﬃcult to apply to more
traditional emergency department settings. Continuation of
parental opioids and NSAIDs after admission is common
practice, often using patient-controlled analgesia systems in
older children and adolescents [406], but large randomized
studies are not available to provide an evidence base for
practice. Adequate pain management can be compromised
by the occurrence of tolerance or hyperalgesia, potentially by
excessive dosing of opioids.
Although there are few studies documenting the preva-
lence of persistent or “chronic” pain in children with SCD,
most clinical experience suggests that condition is infrequent
in children, but does occur in adolescents. However, there
are no controlled trials of pharmacologic therapies for ado-
lescents with SCD and persistent pain. There is experience
with cognitive-behavioral therapies for other persistent pain
conditions in adolescents [424], and cognitive-behavioral
therapy (CBT), relaxation therapy, and biofeedback all
produce significant and positive eﬀects on pain reduction,
so this experience suggests their likely eﬀectiveness in
adolescents with persistent sickle pain. Because traditional
behavioral and CBT interventions center on the development
of pain coping skills, they may be biased toward a primary
focus on pain relief. Acceptance and commitment therapy
(ACT), as an extension of traditional CBT, emphasizes the
importance of accepting pain symptoms and working toward
valued goals, using interventions such as exposure, cognitive
defusion, and mindfulness, deemphasizes pain relief and
focusing goals toward enhancing daily functioning, and may
be more appropriate in the setting of persistent pain [425].
8. Adult Pain Syndromes
Pain dominates the clinical picture of SCD in general and
sickle cell anemia in particular. Many of the complications
of sickle cell disease are associated with either acute or
chronic pain. Acute chest syndrome and hepatic cholestasis,
for example, are associated with acute pain. Leg ulcers and
avascular necrosis, on the other hand, are often associated
with chronic pain. Management of these types of pain is
associated with themanagement of the complication in ques-
tion as will be discussed below under specific organ/tissue
damage. This section will address sickle cell pain that is not
associated with complications of the disease but itself is a
major complication of SCD.
Sickle cell pain is often classified as either acute or
chronic. The acute type is the recurrent painful crisis that
often requires treatment in the emergency room, day unit,
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or hospital with parenteral analgesics, mostly opioids. Pain
that occurs between the acute episodes is usually milder and
treated at home with oral analgesics and is often referred
to as chronic pain. Although this classification is somewhat
arbitrary, nevertheless management of sickle pain is based on
these assumptions as will be discussed below.
8.1. Acute Pain. The acute sickle cell painful crisis (also
known as acute painful episode or event) is the hallmark
of sickle cell disease in both children and adults. It is the
number one cause of hospital admissions in adults with 95%
of admissions due to acute painful crises [426]. The painful
crisis often precedes the onset of other complications of the
disease such as acute chest syndrome and acute multiorgan
failure. About 50% of cases of acute chest syndrome occur
in patients a few days after admission to the hospital with
acute painful crises [427]. Moreover sudden death is known
to occur during a painful crisis or shortly after discharge from
the hospital [428, 429].
The frequency of acute pain crises in patients varies
within and between individuals from rare occurrences
during a lifetime to many times a month [430]. About
30% of patients have rare or no pain episodes, 50% have
occasional episodes, and 20% have weekly or monthly
episodes requiring medical attention [431]. The frequency
of pain episodes increases late in the second decade of life
and decreases in frequency after the fourth decade for reasons
that are not understood [430, 432]. Frequency of more than
3 episodes a year is associated with a reduced life expectancy
[432]. A small number of patients account for the majority of
patients requiring healthcare for acute pain episodes [432].
There are at least three sets of known predisposing events
that seem to predict the frequency and severity of the acute
sickle cell painful crisis. These are genetic, cellular, and
environmental/epigenetic factors.
Genetic factors include Hb F level, the coinheritance
of thalassemia (alpha or beta), the coinheritance of other
hemoglobin variants (such as Hb C), beta haplotypes,
epistatic gene modifiers, and gender. The higher the level
of Hb F the milder is the disease and the less frequent
are the painful crises [433–435]. The coinheritance of alpha
thalassemia, beta+ thalassemia, and Hb C decreases the
frequency of crises. The Senegalese beta haplotype seems to
be associated with less crises than the Benin or the CAR
haplotypes [436]. Females are admitted less frequently to
the hospital than males but they have longer hospital stay
[426, 437].
Cellular factors associated with decreased RBC deforma-
bility and increased number of dense cells in the steady state
have salutary eﬀect, most likely because these are associated
with more severe anemia and, hence, relatively decreased
whole blood viscosity [438, 439]. Patients with sickle cell
anemia and relatively high hemoglobin levels are more likely
to experience more frequent crises than those patients with
lower Hb levels [440].
Nocturnal hypoxia, sleep apnea, and nutritional factors
such as vitamin A deficiency are environmental factors
amenable to preventative therapy [441, 442].
Patients relate onset of pain to emotional stress, changes
in weather, exposure to cold, dehydration, infection, fatigue,
and overexertion. Major reported factors that seem to
precipitate acute painful crises include dehydration, stress
of any kind (physical, traumatic, physiological, psychosocial,
emotional, etc.), infection, asthma, acidosis, sleep apnea, cli-
mate, and pregnancy [443, 444]. Nevertheless, most painful
episodes are not preceded by an obvious precipitating factor.
Moreover, daily mood and stress predict painful events,
utilization of healthcare facilities, and work activity in adults
with SCD [445].
Anecdotally, many patients report that sudden changes
in temperature seem to precipitate acute painful episodes.
Several studies have found an increased incidence of pain
episodes during cold and rainy weather [446–448]. Others
have disputed this association although these studies were
underpowered because of sample size [449–452]. The eﬀect
of high wind and low humidity is likely to be related to skin
cooling. More recent studies suggest that windy dry weather
and increased air pollution may precipitate pain episodes in
London [453, 454]. The suggestion by many patients that
swimming or exposure to cold water is a precipitant was
directly supported in one study [455].
Pain of the acute crisis is often described as throbbing,
sharp dull, or stabbing in decreasing order of frequency.
Anatomic sites most aﬀected include the back, legs, knees,
arms, chest, and abdomen in decreasing order of frequency
[456]. The intensity of the pain of the acute crisis is typically
>6 on a visual analogue scale, or similar other scales, where
0 denotes absence of pain and 10 indicates the most severe
pain [426, 456].
8.2. Chronic Pain. Chronic pain is pain that does not go away
and lasts for months and even years throughout the lifespan
of the patient. It is usually described as deep, nagging, and
achy in nature that is there all the time. It could be in
the chest, back, abdomen, extremities, neck, or headache. It
resides there without invitation and resists any trial for its
resolution. It usually follows frequent recurrent and severe
acute painful crises. Early and aggressive interventions in
treating acute sickle cell pain may be successful in reducing
the development of chronic pain. The principles of treating
chronic pain are diﬀerent than those of acute pain. The
goal of managing acute pain is to heel the acute injury or
precipitating factor(s). The goal of treating chronic pain is
to restore function. In a sense chronic sickle cell pain is
a spin oﬀ the recurrent acute painful episodes. As such it
becomes a disease by itself due to neuroplasticity of the
central nervous system and central sensitization. To that end,
ambient environmental stimuli that are normally innocuous
become painful to the sensitized patient with chronic pain.
Once chronic pain sets in it is joined by other mal-
adies that enhance its chronicity. These include depression,
anxiety, suﬀering, despair, insomnia, loneliness, helplessness,
and dependence on pain medications. With the onset of
chronic pain there seems to be a process of “re-wiring” the
brain where the threshold for pain perception is lowered
so that ambient environmental stimuli that are normally
painless or mildly painful induce the perception of severe
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Table 3: Principles of management of acute sickle cell pain.
(i) Assessment
(ii) Choice of type of analgesic/dose/route
(iii) Titration to relief/adjuvants
(iv) Maintenance
(v) Identify and treat side eﬀects
(vi) Adjustment for tolerance/rotation
(vii) Tapering
(viii) Switch to oral analgesics
(ix) Specify disposition
pain. Hyperalgesia in this context is the perception of severe
pain generated by stimuli that are normally mildly painful,
and allodynia is the perception of severe pain by stimuli that
are normally painless [443, 457].
Neuropathic Pain. It is usually described as numb, tingling,
lancinating, shooting, or paroxysmal in nature associated
with a sensation of pins and needles. Its severity is also
enhanced by exposure to either cold or heat. This pain was
believed to be secondary to nerve injury whether peripherally
or centrally. This definition has recently been modified by
the International Association for the Study of Pain (IASP) to
include injury and dysfunction of nerves as causes. Persistent
chronic pain and/or its management seem to cause the
perception of neuropathic pain. The pathophysiologic events
leading to this transformation are not well understood also.
Activation of the glia seems to be a possible pathophysiologic
mechanism leading to neuropathic pain [458].
“Breakthrough” Pain. It is another kind of pain often referred
to by care providers following patients with SCD. Literally
this term means the act of breaking through pain relief.
Originally this term was introduced for patients with cancer
pain [459] and was defined as a flair of sudden [457] pain
in patients with cancer pain that were maintained on a
stable dose of oral analgesics to achieve adequate relief.
Such flair is usually sudden and incidental, precipitated by
movement, and may last from a few seconds to a few hours.
Recommended management includes the administration of
short-acting analgesics via a route that achieves immediate
relief such as parenteral or transmucosal routes. Details of
the definition and management of breakthrough pain are
controversial to date, and its application to other types of
pain seems arbitrary. Health care providers treating patients
with sickle cell pain use the term “breakthrough” pain loosely
for any pain that occurs in patients taking analgesics daily
for chronic pain and treat it with short-acting oral analgesics
that are the same or diﬀerent than the long-acting analgesics
the patients are already taking. Moreover the short-acting
analgesic is often given several times a day in cumulative
excessive doses that are as high as or even higher than the
daily dose of the long-acting opioids the patients are already
taking. Thus this kind of practice is not for breakthrough
pain but rather an administration of extra or rescue doses
Table 4: Nonpharmacologic management of pain.
(i) TENS (i) Relaxation
(ii) Vibration (ii) Virtual reality
(iii) Massage (iii) Meditation
(iv) Heat or ice packs (iv) Self-hypnosis
(v) Menthol rub (v) Acupressure
(vi) Therapeutic exercise (vi) Acupuncture
(vii) Music (vii) Biofeedback
of analgesics for pain that is inadequately treated in the first
place and implies that the dose of the long-acting analgesic
used should be increased to achieve better pain relief.
Other Types of Pain. They include postoperative pain and
iatrogenic pain due to therapeutic interventions. These are
not unique to SCD and, hence, will not be discussed in this
paper.
8.3. Management. Eﬀective management of acute pain in
the emergency room, day unit, or in the hospital depends
on systematically following certain sequential steps (Table 3)
that start with thorough assessment coupled with the utiliza-
tion of nonpharmacologic and pharmacologic modalities of
therapy culminating in a plan for discharge and followup.
8.4. Assessment. Assessment is the basis of eﬀective pain
management. It should be done before and periodically
after the initiation of analgesic therapy [443, 460, 461].
The patient’s self-report is the most important factor in the
hierarchy of pain management. Other factors in the process
of assessment should include the presence or absence of
other complications of the disease, such as infection, family
members report, and vital signs, including temperature,
blood pressure, pulse, respiratory rate, and pulse oximetry.
The patient’s self-report should include multidimensional
scales describing intensity, quality, location, distribution,
onset, duration, mood, sedation, pain relief, and factors that
aggravate or relieve pain [460, 462].
The intensity of pain can be assessed by any of several
available scales, such as the visual analogue scale, verbal scale,
numerical scale, or Wong-Baker faces scale for children. It is
important, however, to stick to one scale and use it routinely,
so that both the patient and provider become familiar with it
and with its significance to a particular patient. Nociceptive
sickle cell pain typically is sharp or throbbing in nature. Pain
that is burning, shooting, lancinating, or tingling suggests the
presence of a neuropathic component that entails the use of
certain adjuvants mentioned below [443, 460].
8.4.1. Nonpharmacologic Management of Pain. Table 4 lists
the various approaches to nonpharmacologic therapy. It
is important to note that these approaches do not apply
to all patients all the time. Certain methods may appeal
to some but not all patients. Counseling the patient in
order to determine which nonpharmacologic method the
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Table 5: Classification of opioid analgesicsg.
(1) μ Agonists
Codeine: O, P
Hydrocodone: O
Morphine: O, P, IR, CR
Hydromorphone: O, P, IR, CR
Oxycodone: O, IR, CR
Meperidine: O, P, IR
Fentanyl: TD, OTM, OBU, P, IR, CR
Oxymorphone: O, P, IR, CR
Methadone: O, P, LA
Levorphanol: O, P, LA
(2) Partial agonists
Buprenorphine: P, OSLG, TD
(3) Mixed agonists antagonists
Pentazocine: O, P, IR
Nalbuphine: P, IR
Butorphanol: P, IN, IR
(4) Others
Tapentadol: O, IR
Tramadol: O, IR, CR
O; oral; P; parenteral; IR; immediate release; CR; controlled release; TD;
transdermal; OTM; oral transmembranous; OBU; oral buccal; LA; long-
acting; OSLG; oral sublingual; IN; intranasal.
patient chooses would be associated with the most desirable
outcome. Although there are no well-controlled clinical trials
of the eﬃcacy of these methods in the management of sickle
cell pain, there are many anecdotal reports of their eﬃcacy in
pain management.
8.4.2. Pharmacologic Management of Pain. Pharmacologic
management of pain includes three major classes of com-
pounds: nonopioids, opioids, and adjuvants [443, 460, 461].
A major diﬀerence between nonopioids and opioids is that
the former has a “ceiling eﬀect,” a term that refers to a
dose above which there is no additive analgesic eﬀect [457,
458, 463]. Nonopioids include acetaminophen, nonsteroidal
anti-inflammatories (NSAIDs), topical agents, tramadol, and
corticosteroids.
8.4.3. Opioid Analgesics. These compounds have fewer sys-
temic adverse eﬀects than NSAIDs [464], but their use in
SCD is associated with many myths about drug-seeking
behavior and addiction. Four major classes of opioids there
exist agonists, partial agonists, mixed agonists-antagonists,
and antagonists (Table 5).
Opioid agonists are most often used in the management
of sickle cell pain. They decrease or modify the perception
of pain at the level of the central nervous system. They
exert their eﬀect by binding to μ-, κ-, and, to a lesser
extent, δ-receptors [457, 458, 464]. Opioid agonists can be
administered by several routes (e.g., orally, subcutaneously,
intramuscularly, intravenously, transdermally) andmethods,
including continuous intravenous drip, patient-controlled
analgesia (PCA) pump, and intermittent injection. Mor-
phine and hydromorphone are the major opioid analgesics
used in the treatment of severe acute pain in the emergency
department, day unit, and hospital. Controlled released
opioids, such as controlled-release (CR) oxycodone andmor-
phine CR, are useful in the management of chronic pain and
in combination with short-acting opioids for breakthrough
pain. Fentanyl is available in parenteral, transdermal, and
transmucosal formulations. Methadone is a true long-acting
opioid that can be used in combination with short-acting
opioids in selected patients.
Adverse eﬀects of opioid analgesics include itching,
nausea, vomiting, sedation, and respiratory depression.
Seizures may be associated with opioids, especially with the
prolonged use of meperidine (pethidine) and the consequent
accumulation of its major metabolite, normeperidine, in
some patients. The eﬀects of meperidine and normeperidine
on seizure induction are more pronounced in the presence
of renal disease. Tolerance and physical dependence occur in
some patients, but addiction is rare [430]. Methadone may
be associated with prolongation of the QTc interval [465].
Opioid analgesics have no ceiling eﬀect (with the possible
exception of codeine); hence the only limiting factor on
their dose is adverse eﬀects. Severe sedation and respiratory
depression are the most important adverse eﬀects. Hospital-
ized patients receiving opioid analgesics on a regular basis
should be monitored for their respiratory rate and sedation
level. A respiratory rate of less than ten per minute or severe
sedation justifies skipping, decreasing, or delaying the dose
or discontinuing the opioid in question until the depressive
eﬀects disappear. Opioid analgesics should be used carefully
in patients with impaired ventilation, asthma, increased
intracranial pressure, and liver failure. The presence of
acetaminophen in combination with codeine or oxycodone
limits the daily dose that may be safely used so that the
maximum allowable dose of acetaminophen is not exceeded.
The FDA has recently decreased the maximum allowable
daily dose of acetaminophen to 3000mg/day instead of the
previous 4000mg/day [466].
Providers who prescribe opioids for patients with sickle
cell pain must be cognizant of the current legal require-
ments. Specifically and besides prescribing enough opioids
to optimize pain relief, providers must institute measures
to minimize the risk of misuse, abuse, or diversion of
the prescribed opioids. Specific approaches to these rec-
ommendations have been published by the American Pain
Society in collaboration with the American Academy of Pain
Medicine [467, 468]. Most important among these include
the establishment of a consent form, treatment plan, random
urine drug testing and thorough documentation of the plan
of management, and followup of each patient who receives
opioid prescriptions on a regular basis.
Adjuvants. They include antihistamines, antidepressants,
benzodiazepines, and anticonvulsants. These are heteroge-
neous compounds that potentiate the analgesic eﬀect of
opioids, ameliorate their side eﬀects, and have their own
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mild analgesic eﬀect. The role of selective serotonin reuptake
inhibitors in sickle cell anemia is not clear at present.
Adjuvants must be used with care, and patients should be
monitored carefully when receiving them. Adjuvants also
have adverse eﬀects, some of which precipitate or worsen
manifestations of sickle cell anemia [430].
Acute painful episodes of mild or moderate severity are
usually treated at home using a combination of nonpharma-
cologic and pharmacologic modalities. Home treatment of
pain usually follows the three-step analgesic ladder proposed
by the World Health Organization [469]. Mild pain is treated
with nonpharmacologic agents alone or in combination with
a nonopioid. More severe pain entails the addition of an
opioid with or without an adjuvant.
Patients with chronic sickle cell pain are best managed
with a combination of long-acting opioids and a short-acting
opioid for breakthrough pain. Again, anecdotal reports sug-
gest that this approach decreases the frequency of admissions
to the emergency department or hospital, but data to confirm
this finding are not available to date. Oxycodone CR appears
to be unique in that it has both an immediate analgesic
eﬀect and a delayed long-acting one. These properties have
made oxycodone CR popular among drug abusers who have
learned to remove the mesh and release a high dose of
pure oxycodone that has an immediate “euphoric” eﬀect
[470]. Care providers should exert caution in prescribing
oxycodone CR and other opioids and should keep detailed
records of assessment and plans of management of their
patients.
8.4.4. Preventative Therapies. Measures to reduce the mor-
bidity and mortality of sickle cell anemia include pro-
phylactic penicillin therapy in infants and children [471]
and hydroxyurea [472–474]. Although hydroxyurea was first
approved for adults with sickle cell anemia and sickle-β0-
thalassemia, results of the recently described Baby HUG
trial justify its use in children as well [475]. Patients who
responded to hydroxyurea experienced significant reduction
in the incidence of acute painful episodes, acute chest
syndrome, transfusion requirement, andmortality [473, 474,
476]. The beneficial eﬀects of hydroxyurea are thought to be
due to its induction of Hb F production. Any increase in Hb
F level appears to have a salutary eﬀect on the clinical picture
of sickle cell anemia.
9. Pulmonary Complications
9.1. Acute Chest Syndrome. The clinical manifestations of
acute chest syndrome (ACS) complicating SCD include chest
pain, tachypnea, fever, hypoxia, dyspnea, cough, leukocy-
tosis, decreasing Hb level, and new infiltrates on chest X-
ray [477–479]. Not all these signs and symptoms occur in
all cases of ACS with the exception of the new pulmonary
infiltrates which are considered the sine qua non for the
diagnosis. The presence of new infiltrates with some of the
other signs and symptoms is usually enough to make the
diagnosis. An infiltrate is new when compared to a previous
radiograph with no infiltrate. If a previous radiograph is
not available, the infiltrate in question is considered as new.
It is obvious from this description that there are gaps in
making an accurate diagnosis. For example, there is no
agreement on the number and nature of the accompanying
signs and symptoms to make the diagnosis. Moreover, an
occasional patient may have all the signs and symptoms
mentioned above with no new infiltrate on chest radiograph
thus generating a dilemma for the provider. Suﬃce to say is
that the ACS, like other syndromes, is a spectrum of clinical
manifestations that vary from the mild to the very severe.
Observation and careful monitoring on a daily basis or more
often if needed are most important in ruling the diagnosis in
or out.
The incidence of ACS is age and genotype dependent
with no diﬀerence between the sexes. It is about three times
more common in young children than in adults but more
severe in adults [478, 479]. ACS is most common in SS,
S-β0-thalassemia, Hb SC disease and S-β+-thalassemia in
decreasing order of frequency. Coexistent α gene deletion, the
platelet count, and the mean corpuscular volume (MCV) of
RBC do not seem to aﬀect the incidence of ACS [478]. The
incidence of ACS decreases in the presence of high Hb F level
and severe anemia but is directly proportional to the steady-
state WBC count [478]. ACS is closely associated with acute
painful crises especially in adults [480, 481]. About 50% of
ACS episodes occur after hospital admission for acute painful
crises [480]. Moreover, ACS seems to be the most common
cause of death among patients and the secondmost common
cause of hospitalization of patients with SCD [482–485].
Causes of ACS include pneumonia, bone marrow fat
embolism, pulmonary infarct due to in situ sickling,
rib/sternal infarction, infection, and pulmonary embolism
[480, 486–488]. About 50% of patients with ACS have no
identifiable etiology [480]. Rib or sternal infarction leads to
hypoventilation due to splinting with consequent atelectasis
and retention of secretions that may initiate an infectious
process [486, 487]. Infectious etiologies of ACS include typi-
cal and atypical bacteria, typical and atypical viruses, or other
organisms. Specific infectious etiologies include chlamydia,
mycoplasma, respiratory syncytial virus, coagulase-positive
S. aureus, S. pneumonia, Mycoplasma hominis, parvovirus
and rhinovirus in decreasing order of frequency [480]. In
situ sickling leading to in situ thrombosis/pulmonary infarct
is diﬀerent from the usually known PE due to emboli from
the lower extremities or pelvis. The prevalence of apparent
PE in patients with SCD is higher than in non-SCD African-
American patients with the same age despite the fact that the
prevalence of DVT was comparable in both groups [489].
This discrepancy suggests that the apparently surplus PE in
patients with SCD is most likely due to in situ thrombosis.
This diﬀerentiation is important in deciding whether long-
term anticoagulation is indicated or not.
Prospective multicenter study of ACS in SCD showed
that bone marrow/fat embolism is more common than
previously thought [480]. Severe sickle cell pain in long
bones followed by dyspnea, hypoxia, and fever is the clinical
picture suggestive of fat embolism. Tissue infarction of the
bone marrow within long bones seems to be the source of
fat and necrotic tissue that finds its way to the blood stream
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and from there to the lungs, brain, or other organs. The
diagnosis of fat embolism entails the identification of fat-
laden macrophages (fat bodies) in blood, urine, induced
deep sputum, or, better, in bronchoalveolar lavage fluid
obtained by bronchoscopy [490].
Management of ACS utilizes multiple modalities in order
to prevent possible catastrophic outcomes. The most impor-
tant aspect of management is to maintain adequate venti-
lation. In mild cases incentive spirometry may be suﬃcient
to achieve this. In severe cases, however, mechanical venti-
lation in the intensive care unit is essential. Once adequate
ventilation is maintained, specific treatment includes oxygen,
antibiotics, simple blood transfusion or exchange transfu-
sion, judicious use of analgesics, bronchodilators, careful
hydration, and possible vasodilators. Incentive spirometry
prevents splinting and atelectasis and may actually prevent
ACS in patients who have rib infarction [487]. Intravenous
antibiotics are indicated since it is diﬃcult to rule out pneu-
monia or infected lung infarcts. A combination of a third
generation cephalosporin and a macrolide or a quinolone
antibiotic should be used to cover typical and atypical
pathogens. Simple transfusion or exchange transfusion is
indicated in patients with worsening respiratory function
[491]. The beneficial eﬀects of blood transfusion may not
be due simply to decreasing the proportion of sickled RBCs,
and other mechanisms may be involved. These include (1)
an immunomodulatory mechanism by which inflammatory
cytokines (IL-8 in particular) bind to the Duﬀy antigen
present on transfused RBCs, but often absent on RBCs of
African-Americans [490]; (2) the albumin that is present in
transfused units or used in blood exchange may bind free
fatty acids, thus neutralizing their damaging eﬀect on the
pulmonary endothelium.
Although intravenous steroids in children with ACS
may be beneficial [492], their use in adults with ACS is
controversial. Huang et al. [493] reported two adult patients
with sickle cell disease whose clinical picture deteriorated
and was complicated by worsening pain, fat embolism,
and coma after steroid therapy. Other investigators had
similar experience with steroids. [494, 495] Adults, unlike
children, have more adipose tissue that may hypertrophy
with steroids, increasing the chances of fat embolization.
Moreover, steroids may induce or worsen avascular necrosis
which is more common in adults than in children. Manage-
ment of ACS due to proven PE includes anticoagulation as
used in PE in general. The role of anticoagulation in patients
with ACS due to in situ thrombosis is unknown.
Excessive opioid analgesics may precipitate acute chest
syndrome due to their depressive eﬀect on respiration. This
recommendation should be considered carefully. Opioids
have a few systemic side eﬀects, and careful monitoring of
their use ensures their safety. They should be discontinued if
the respiratory rate is ≤10/minute and their adverse eﬀects
can be quickly reversed with opioid antagonists. NSAIDSs,
on the other hand, have considerable systemic side eﬀects
that may not be readily obvious. NSAIDSs decrease the
levels of prostaglandins, prostacyclin, and prostanoids that
are essential in modulating the vascular tone of smooth
muscle and renal blood flow. Thus, NSAIDSsmay worsen the
clinical picture of ACS due to their vasoconstrictive eﬀects
and bronchospasm. NSAIDSs are contraindicated in asthma
for the same reasons.
The use of nitric oxide, a vasodilator, in patients with
SCD supports a possible role of this agent in themanagement
of ACS [496]. Other vasodilators such as prostacyclin
and calcium channel blockers have not been reported in
the management of ACS. Another recent investigational
approach to treat ACS includes the use of purified poloxamer
188 (Flocor), which is a nonionic surfactant [497, 498]. It is
hypothesized that this agent reduces blood viscosity, prevents
adhesion of RBCs to vascular endothelium, and improves
microvascular blood flow.
The role of vasodilators in the management of SCD
in general and ACS in particular is not finalized. Nitric
oxide (NO) had a beneficial eﬀect on painful crises in
children [499] and in adults in the emergency room setup
[500, 501]. It use on hospitalized patients with painful crises
had no beneficial eﬀect [502]. An open trial using purified
poloxamer 188 (Flocor), a nonionic surfactant, in patients
with ACS showed no benefit [497]. Other vasodilators such
as prostacyclin and calcium channel blockers have not been
reported in the management of ACS.
10. Pulmonary Hypertension
10.1. Prognosis and Prevalence of PHT in SCD. Pulmonary
hypertension (PHT), which is defined as mean pulmonary
artery pressure (PAP) of 25mmHg, determined by right
heart catheterization (RHC), is one of the leading causes
of mortality and morbidity in adults with sickle cell disease
(SCD). Interestingly, elevated systolic PAP, derived from
echocardiography-based tricuspid jet velocity (TRJV), if
present in adult patients with SCD, also portends a poor
prognosis.
Castro and colleagues were amongst the first to study
sickle PHT and determine the relationship of PHT (deter-
mined by RHC) to patient survival. They studied 34 adult
patients with SCD and showed that mean PAP had a
significant inverse relationship with survival, with each
increase of 10mmHg in mean PAP associated with a 1.7-
fold increase in the rate of death; the median survival for
patients with PHT was 25.6 months, whereas for patients
without PHT, the survival was >70% at the end of the 119-
month observation period, showing that onset of PHT in
patients with SCD significantly shortens their survival [503].
Gladwin et al. subsequently reported that elevated systolic
PAP (derived from echocardiography based TRJV ≥2.5m/s)
strongly correlated with an increased risk of death (odds
ratio, 10.1); the risk of death increased significantly with
TRJV >3m/s [504]. Recently, two large studies in patients
with SCD have determined that PHT (determined by using
RHC, the gold standard for diagnosis of PHT) is associated
with poor survival of adult patients with SCD [505, 506].
Following the report by Gladwin et al. [504], TRJV
>2.5m/s (or increased peak/systolic PAP) became erro-
neously synonymous with sickle PHT for the next 6 years,
until some recent critical reviews of the literature [507, 508]
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and two recent reports on RHC on patients with TRJV
>2.5m/sec [505, 506] which highlighted the fact that while
TRJV ≥2.5m/s may be uniformly associated with poor
outcome in adults with SCD, it is not equivalent to PHT in
themajority of patients that have a high TRJV (>2.5m/s); the
predictive value of TRJV is about 25–33% [505, 506].
PHT has been reported to be present in 6–33% of
adult patients with SCD in diﬀerent studies, with most
studies using echocardiography-based TRJV to predict PHT.
It is becoming increasingly clear that echocardiography-
based studies (tricuspid regurgitation jet velocity; TRJV)
overestimate the prevalence of PHT in nearly two-thirds of
adults with SCD [504], while RHC data suggest a lower
prevalence in 6–10% of patients [505, 506]. That said,
elevated TRJV in adults with SCD, regardless of whether
they have RHC-proven PHT or not, predicts a poor survival.
Hence high TRJV is likely indicative of other underlying
cardiac pathologies, such as ventricular diastolic dysfunction,
vasculopathy/endothelial dysfunction, or perhaps a sickle
cardiomyopathy resulting from the chronic hypoxic stress on
the myocardium. Recently, Knight-Perry et al. found cardiac
structural and functional abnormalities in patients with high
peak systolic PAP (TRJV >2.5m/s). They assessed RV and LV
structure and function via echocardiography in adults with
SCD. Patients who had high TRJV (>2.5m/s) had higher left
atrial volumes, LV and RV filling pressures, and reduced LV
and RV compliance [509]. More recently, DeBaun and col-
leagues have reported diastolic dysfunction in patients with
SCD [510]. Therefore, other parameters of echocardiography
besides TRJV, and a second imagingmodality, such as cardiac
MRI should be assessed in addition to TRJV.
In children, TRJV defined of systolic PHT is more
controversial, where high TRJV ≥2.5m/s is not reproducible
[511]. Pashankar and colleagues conducted a longitudinal
followup of 54 children. Only half the children with elevated
TRJV showed persistently higher TRJV at followup, and
most of those with persistently elevated TRJV were those
with TRJV >2.7m/s [511, 512]. Furthermore, elevated TRJV
(TRJV >2.5m/s) has not been shown to carry the dismal
prognosis that is seen in SCD adults with high TRJV. A large
prospective study in over 400 children with SCD and age-
matched controls found that TRJV up to 2.6m/s was found
in normal children, and TRJV >2.6m/s in children with SCD
was associated with an increased hemolytic index [513]; a
followup of 160 of adults and adolescents that had high TRJV
or diastolic dysfunction from this cohort showed a higher
risk of developing exercise intolerance, as measured by a 6-
minute walk distance [514].
10.2. Pathophysiology of PHT in SCD. The last six years have
seen an upsurge of studies on the pathophysiology of PHT
in SCD. In clinical studies, high TRJV is associated with
a higher rate of hemolysis, renal insuﬃciency, leg ulcers,
increasing age, low exercise capacity and high levels of N-
terminal probrain natriuretic peptide or vascular cell adhe-
sion molecule-1, and a hypercoagulable state [513, 515–522].
Factors that have been implicated in PHT in SCD include
endothelial dysfunction, pulmonary vasoconstriction, and
vascular remodeling. All of these factors are associated
with chronic hemolysis, hypoxia, hemostatic activation, and
inflammation [518–520].
The hemodynamic etiology of PHT is multifactorial;
studies show that elevated systolic PAP is associated with
either pulmonary arterial hypertension, pulmonary venous
hypertension, and PHT secondary to a hyperdynamic state
associated with right and/or left ventricular hypertrophy
and diastolic dysfunction [510, 523–525]. In a recent hemo-
dynamic assessment, patients with SCD-associated PHT
(diagnosed by RHC) were found to either have pulmonary
arterial hypertension or venous PHT, both associated with
severe limitations in exercise capacity in the 6-minute walk
test [525]. Myocardial dysfunction is also being increasingly
reported in patients with SCA, suggestive of a “sickle
cardiomyopathy”, ventricular remodeling and even ischemia
[510, 526–530].
Reduced nitric oxide bioavailability has been implicated
in the pathophysiology of PHT in SCD and other hemolytic
anemias [513, 517, 518, 531]. This has been attributed to
reduced argninine levels, from the increased RBC-derived-
arginase in SCD [518, 531–533]. ET-1 and nitric oxide (NO)
are opposing pulmonary vasoactive factors that regulate
pulmonary vascular tone [521, 522]. Studies have shown
that hemolysis is associated with PHT in SCA [522].
Hemolysis results in quenching of NO by extracellular
hemoglobin thereby reducing the bioavailability of NO [522,
523].
ET-1, a potent pulmonary vasoconstrictor, is elevated in
SCA patients with PHT [505, 521, 524]. ET-1 is normally
induced in endothelial cells in response to hypoxia as
a result of activation of HIF-1α [524–526]. ET-1 recep-
tor antagonists, used for the treatment of primary PHT
[527], have been found to be beneficial in sickle-Antilles-
hemoglobin D mice [528], indicating the important role
of ET-1 in PHT in SCA. Malik and Kalra have shown
that placenta growth factor, an angiogenic growth factor
produced in high amounts by sickle erythroid cells, induces
hypoxia-independent expression of hypoxia inducible factor-
1 (HIF-1α). HIF-1α then induces expression of the potent
pulmonary vasoconstrictor endothelin-1 (ET-1) [534], and
a profibrotic and procoagulant factor, plasminogen activator
inhibitor-1 (PAI-1) from human pulmonary microvascular
endothelial cells (HPMVECs) [535]. Indeed, ectopic expres-
sion of placenta growth factor in normal mice, using a
lentiviral vector or an adenoviral vector to generate similar
placenta growth factor levels seen in sickle mice, resulted
in increased ET-1 and plasminogen activator inhibitor-1
(PAI-1) production and development of PHT, similar to
PHT seen in sickle mice [535, 536]. These findings were
corroborated by Kato and colleagues in patients with SCD;
in these patients, increased plasma placenta growth factor
levels were significantly associated with increased plasma
ET-1 levels and increased TRJV derived systolic PAP [536].
The association of placenta growth factor and high TRJV
was confirmed independently by Ataga and colleagues [537].
Hence, it appears that while there is reduced bioavailability
of NO, a potent pulmonary vasodilator, ET-1, a potent
pulmonary vasoconstrictor, is increased, resulting in PHT.
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A hypercoagulable state and microthrombi have been
shown to contribute to PHT in other diseases. SCD is
a hypercoagulable state. Studies show that SCD patients
have elevated steady-state plasma levels of circulating tissue
factor [529] and PAI-1, both of which further increase
during sickle vaso-occlusive crises [530, 531]. Elevated PAI-
1 has been implicated in primary PHT [509, 510]. The
prothrombotic state may predispose patients to PHT and
stroke [518, 519, 532]. In addition to the role of PAI-1 in
coagulation, PAI-1 also has been shown to be responsible for
development of pulmonary fibrosis [533], a feature of PHT.
The expression of PAI-1 is also modulated by other stimuli
such as hypoxia, TGF-β, insulin, and lipopolysaccharide
[534–537]. Our group has shown that PAI-1 is directly
induced by the erythroid cell-derived placenta growth factor
[535].
Recently, albuminuria in SCA has been associated with
high TRJV [538], an association which may just be coin-
cidental, since both PH and SN develop with cumulative
chronic organ damage with increasing age. The association
of albuminuria has also been reported in a longitudinal
followup study of children where a higher percentage of
albuminuria was observed in the subset of children with high
TRJV [512].
10.3. Therapeutic Modalities for Sickle PHT. Currently, there
are limited data on the eﬀects of any specific treatment
modality for PH in patients with SCA. Endothelin-1 receptor
antagonists have been tried, are safely tolerated, and show
some hemodynamic and functional improvement [526, 539].
Indeed, bosentan was able to reverse PHT in a mouse model
of sickle cell disease [540]. However, the clinical trial of
bosentan was closed due to inadequate accrual.
A multicenter trial of sildenafil was initiated to improve
NO bioavailability (Walk-PHASST) [514, 541]. Here patients
with high TRJV were given sildenafil and a detailed assess-
ment of RV function, and exercise tolerance was assessed.
Unfortunately, this trial had to be prematurely terminated
due to increased painful vaso-occlusive events reported with
sildenafil.
Oral arginine supplementation was attempted in a mul-
ticenter trial to improve NO bioavailability, but the results
of this trial were inconclusive (unpublished data). Chronic
transfusions and hydroxyurea are currently being tried for
patients with high TRJV/PHT, and the results of these trials
are eagerly awaited. Currently, there is no targeted therapy
available for patients with SCD that develop PHT. Therefore,
newer therapies for sickle PHT are desperately needed.
10.4. Summary. PHT is one of the leading causes of morbid-
ity and mortality in adult patients with SCD. However, there
are significant gaps in knowledge in the predictors, accurate
screening modalities, pathophysiology, and treatment of
sickle PHT. PHT is defined as a mean pulmonary arterial
pressure (PAP) of ≥25mmHg by RHC, but the invasive
nature of this modality is prohibitive to using RHC as a
screening tool. There is lack of an accurate noninvasive
screening test for PHT in SCD. In children, where RHC
is rarely performed, data on PHT is much more limited
and restricted to echocardiography-based projections, which
are less predictive of the prognosis than similar estimations
in adults. Echocardiography-obtained tricuspid regurgita-
tion jet velocity (TRJV) is used to estimate peak/systolic
pulmonary artery pressure. Recent studies show that high
TRJV/Peak PAP only predicts PHT in 25–33% of adult
patients with SCD. Nevertheless, high TRJV is associated
with poor prognosis in multiple studies, suggesting that
additional cardiac/endothelial pathology leads to increased
systolic PAP in SCD and portends a poor prognosis. The
prognosis of PHT in SCD is poor, with the development
of PHT associated with a 40–50% risk of death within 2-
3 years (odds ratio of 8–15) [504, 542, 543]. Second, not
all patients with SCD develop PHT, and biomarkers that
define the subgroup of patients destined to have PHT are not
well defined. Hence, novel/refined noninvasive diagnostic
modalities and biomarkers are much needed to detect
the early onset of PHT in SCD in susceptible patients
and timely therapeutic intervention. The pathogenesis of
PHT in SCD is likely multifactorial, including hemolysis,
impaired nitric oxide bioavailability, chronic hypoxemia, and
increased endothelin-1, a potent pulmonary vasoconstrictor,
mediated via hypoxia and via the erythropoietic cell-derived
placenta growth factor, chronic thromboembolic disease,
and asplenia [516]. The hemodynamic etiology of PHT is
multifactorial and includes pulmonary arterial hypertension,
pulmonary venous hypertension, and PH secondary to
a hyperdynamic state associated with right and/or left
ventricular hypertrophy and diastolic dysfunction [510, 523–
525]. Finally, therapeutic options of PHT in patients with
SCD are extremely limited. Clinical trials using bosentan (an
endothelin-1 receptor blocker) [539] and sildenafil (Walk-
PHASST) [541] had been initiated in patients SCD with
PHT, but could not be completed due to lack of accrual
in the former trial, and increased painful events secondary
to sildenafil, in the latter. Therefore, currently, there is no
proven beneficial treatment for SCD patients that develop
PHT.
11. Renal/Genitourinary Complications
11.1. Sickle Nephropathy
11.1.1. Introduction. The kidney appears to get aﬀected in
several diﬀerent ways in sickle cell disease (SCD). Children,
and even infants with SCD have hyposthenuria/urine con-
centrating defect (UCD), supranormal glomerular filtration
rate (GFR) and proximal tubular function, and an impaired
ability to acidify urine or excrete potassium (reviewed in
references [544–547]). A majority of patients with SCD have
evidence of microscopic hematuria and may even develop
gross hematuria from renal papillary necrosis. Older individ-
uals have been found to have glomerulopathy, that manifests
as microalbuminuria (MiA, defined as urine albumin of
30–300mg/g urine creatinine), macroalbuminuria (MaA,
defined as urine albumin >300mg/g urine creatinine), or
end-stage renal disease (ESRD) [544, 545, 548, 549]. Studies
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show that gross proteinuria and ESRD are observed in 15
to 30 percent of patients with SCD [550, 551]. Kidney
biopsies reveal enlarged glomeruli, and the most common
glomerular lesion in sickle nephropathy (SN) is focal and
segmental glomerulosclerosis (FSGS), while membranous
glomerulopathy has also been observed in some cases. We
will review the literature on SN with respect to (1) abnormal
hemodynamics and hematuria, (2) tubular defects, and (3)
glomerulopathy.
11.1.2. Abnormal Hemodynamics. The renal plasma flow and
increased GFR are increased in SCA, possibly from the com-
pensatory hypersecretion of vasodilator prostaglandins in
response to hypoxia-induced sickling [552]. GFR decreases
during adolescence to normal levels, and in older adults,
it is subnormal. Inducible nitric oxide synthase (iNOS) is
increased in the glomeruli and distal nephrons in sickle
mice secondary to hypoxia and is associated with increased
urinary excretion of NO products, suggesting that the
increased NO-induced vasodilatation also contributes to the
increased GFR [553]. There is controversy on the glomeru-
lar ultrafiltration coeﬃcient with some studies showing
increased glomerular permeability, while others showing
reduced ultrafiltration; diﬀerences in results in these studies
probably reflect sampling of patients at diﬀerent stages of SN.
Chronically increased glomerular hyperfiltration and iNOS-
induced peroxynitrite free radical-mediated nitrosylation of
renal proteins promote cellular apoptosis, resulting in FSGS
[553]. Episodic hypoxia-reperfusion injury superimposed on
these renal hemodynamics results in areas of nephron loss
and scarring.
Hematuria. Vascular obstruction from sickled RBCs leads
to microscopic-to-gross painless hematuria, occurring from
medullary congestion and renal papillary necrosis. The
hypoxic (pO2 35–40mmHg), hyperosmolar medullary envi-
ronment promotes sickling. The vasa recta become con-
gested, tortuous, occluded, and hemorrhage, resulting in
painless hematuria. They eventually undergo fibrosis, result-
ing in infarctive papillary damage and necrosis. Hematuria
is often from the left kidney, occurs at any age, and is
even seen in persons with sickle trait. Renal papillary
necrosis is observed in as many as 40–50% of patients
with SCA. Painful hematuria in patients with sickle trait
has been associated with renal medullary carcinoma, a very
aggressive malignancy characteristically seen in this group of
young adults. Damage to the juxtamedullary nephrons and
collecting ducts also occurs and contributes to the UCD and
to tubular defects.
11.1.3. Tubular Defects
Urine-Concentrating Defect. The first manifestation of distal
tubular defect is impaired urine concentrating ability, which
is almost universal in patients with SCD and occurs in chil-
dren, even infants. UCD is transiently reversible before 10–15
years of age with RBC transfusions but becomes irreversible
thereafter [554, 555]. UCD in SCD has been attributed to
polymerization of Hb S in the hyperosmolar, acidic and
relatively hypoxic renal medulla, resulting in sludging of
blood flow in the vasa recta, loss of medullary osmolar
gradient, and eventual destruction of the vasa recta from
vaso-occlusions/thrombosis [556]. UCD is associated with
increased tendency to dehydration and sickling, enuresis and
nocturia [556].
Studies examining UCD, done 5-6 decades back, show
inability to concentrate urine either after water deprivation
or injection of pitressin in patients 1–30 years of age
[554, 555, 557–559]. Interestingly, patients with other sickle
variants, hemoglobin SC or S-thalassemia and sickle trait
also develop UCD, often with a much later onset than those
with homozygous SCD (SS) [554, 558]. Sickle trait with
concurrent α-thalassemia attenuates the defect, proportional
to the reduction in the percentage of hemoglobin S in the
cell, with lower Hb S in the RBC being associated with a later
onset of UCD [560]. Notably, in children, RBC transfusions
can reverse the UCD, but the defect is irreversible after the
age of 10–15 yrs [554, 555]. Hydroxyurea therapy results in
an increase in fetal hemoglobin production and dramatically
reduces the frequency of pain and acute chest episodes in
individuals with SCD [561]. However, hydroxyurea showed
no improvement in UCD in children with hemoglobin SC
disease [561]. A recently completed multicenter BABY-HUG
study [562] should provide useful prospective data on the
usefulness of hydroxyurea in alleviating the UCD in early SN.
Potassium and Acid Secretion. It occurs primarily in the
distal tubules and collecting ducts that are present in the
renal papillae. Therefore, patients with SCD have impaired
ability to excrete acid and potassium [563–565]. Although
hyperkalemia does not occur under normal circumstances,
patients with SCD are unable to excrete a high potassium
load as compared to normal controls [563], and some
patients become hyperkalemic when placed on angiotensin-
converting enzyme inhibitors. Similarly, hyperchloremic
acidosis has been described with mild renal insuﬃciency
[566–568].
Supranormal Proximal Tubular Function. In contrast to distal
tubular defects (which impair urine concentration and acid
secretion), supranormal proximal tubular function is present
in SCD, as evident by increased reabsorption of sodium,
phosphorus, and increased excretion of creatinine and uric
acid in the urine (reviewed in [544, 545]). Hence, plasma
creatinine levels are low in patients with SCD and not a
good biomarker or indicator of renal function, until late
stages of SN, especially since high GFR; creatinine clearance
is also present and hypertension occurs late. Since classic
renal biomarkers are not informative, novel biomarkers are
necessary to monitor for development of SN early in its
course, before the damage becomes largely irreversible.
11.1.4. Glomerulopathy. Glomeruli, especially the juxtam-
edullary glomeruli in young SCA patients, are enlarged
and congested, reaching a size that is 60–80% larger than
normal glomeruli [546]. Glomerulopathy is associated with
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albuminuria, with MiA present in 25% of children <10
years of age, and 45% of adults. MaA develops later with
progression to FSGS. Glomerular lesions are typically FSGS,
mesangial proliferation, endothelial damage and sclero-
sis from hyperfiltration, immune-complex nephritis from
autoantigens released from damaged tubules, and deposition
of iron protein complexes in the kidney. A small proportion
of patients have membranoproliferative glomerulonephritis
with or without immune deposits. The pathogenesis of
glomerulopathy is unknown but presumed to occur from
mesangial phagocytosis of erythrocytes and apoptotic cells.
Macroalbuminuria, especially over 1.5 gm per day, strongly
correlates with progression to renal failure, ESRD, and with
acute chest syndrome [546, 547, 569, 570].
11.1.5. Biomarkers of SN. Standard renal function tests like
serum creatinine and GFR become subnormal in this disease
only when renal damage has become extensive and largely
irreversible. Therefore, good biomarkers that predict early
SN need to be identified. Microalbuminuria is the most
studied biomarker of SN in cross-sectional studies. We
and others have shown that prevalence of albuminuria in
SCD increases with age [570–575]; albuminuria is more
commonly seen in patients with Hb SS disease as compared
to those with Hb SC or Hb S-β+ thalassemia [572]. Guasch
et al. have reported that 70% of adults with SCD have
albuminuria, while only 40% of adults with other types of
sickle cell disease have albuminuria [572]; microalbuminuria
data shows the same trend in children, although a lower
percentage of homozygous SCD patients have albuminuria
[575–578]. Albuminuria could be a useful, albeit delayed
biomarker of SN. Studies in diabetic nephropathy suggest
that glomerular damage has already commenced when
microalbuminuria is detected [579], and not all diabetic
patients who have microalbuminuria go on to develop
gross albuminuria [580]. Whether microalbuminuria is a
predictable biomarker of progressive SN can only be deter-
mined by a longitudinal analysis. Notably, albuminuria in
SCD has also been associated with pulmonary hypertension
[581], suggesting that a common underlyingmechanism that
aﬀects the cardiopulmonary-renal axis may be implicated in
sickle nephropathy and pulmonary hypertension. We have
identified kidney injury molecule-1 (KIM-1) and N-acetyl-
b-D-glucosaminidase (NAG) as two potential biomarkers of
early SN [575] that need to be confirmed in longitudinal
studies as true biomarkers of SN.
11.1.6. Future Directions. SN has remained relatively under-
diagnosed and understudied despite its onset early on
in life: classic biomarkers of renal damage are normal
even in the face of existing chronic sickle kidney disease,
until extensive renal damage has occurred. Supranormal
creatinine excretion in the urine results in lower than normal
serum creatinine; therefore serum creatinine rises only in
late stages of SN. Patients also have higher than normal
renal blood flow and GFR; therefore urinary creatinine
clearance is high from the resulting hyperfiltration, and
subnormal GFR develops only when significant proteinuria
and glomerular damage has developed and is largely irre-
versible [582]. Hence the proportion of patients diagnosed
with SN only represents the tip of the iceberg; consequently,
early interventions that would prevent the progression
of renal damage cannot be applied. Second, the current
paradigm remains that the hypoxic hyperosmotic medullary
environment promotes sickling, causing progressive dam-
age to the vasa recta, tubules, and nephrons over time.
However, no formal studies have been performed on the
molecular basis of SN. Third, not all patients with SCA
develop SN, and it is not clear what factors predict or
promote the progression of SN in susceptible patients.
Finally, despite the known cumulative and progressive nature
of organ damage in SCD, and the onset of SN as early
as infancy, all current knowledge of SN is largely derived
from cross-sectional analysis. There are no systematic
longitudinal studies to characterize its natural history or
progression.
12. Priapism
12.1. Pathophysiology. Priapism is a persistent unwanted and
recurrent painful erectile erection that may last from hours
to days. It is diagnosed by the provider based on patient
self-report. During an episode, priapism can be confirmed
by physical examination of finding a fully erect penis and
complaint of pain in the penis and/or scrotum. There are
no controlled studies on this complication of SCD. Most
reports in the literature are case reports or observational
studies [583–585]. Pathophysiologic mechanisms are not
well understood and seem to pertain to a combination of
hypoxia and impaired penile venous blood flow [586, 587].
The decreased rate of blood flow through the penis during
normal erection allows increased oxygen extraction. As a
result hypoxia promotes sickling with consequent congestion
of the corpora, sludging, further impairment of venous
outflow, and worsening hypoxia. Venous outflow from the
corpora is reduced, and blood aspirated from the corpora
during an episode of priapism is dark and has low pO2 and
low glucose level [588].
12.2. Precipitating and Risk Factors. About 75% of priapism
occurs between midnight and 6 AM and after sexual
intercourse [586, 589, 590]. Acidosis resulting from dehydra-
tion and hypoventilation during sleep may be precipitating
factors. Priapism aﬀects 35% of boys and men [588]. Sexual
intercourse [591], masturbation [592], alcohol intake [593],
infection of the prostate or bladder, recent trauma, andmedi-
cations with autonomic side eﬀects are reported precipitating
factors [594]. In the Jamaican study 16% of patients reported
attacks following intercourse [595, 596]. Most episodes of
priapism, however, have no obvious etiology.
Thrombocytosis, low level of Hb F, and severity of
hemolysis are reported risk factors of priapism [586, 597,
598]. Recent studies have linked the severity of hemolysis
to priapism, leg ulcers, and pulmonary hypertension [597].
These associations, however, have been challenged by other
investigators [599].
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12.3. Classification. Priapism has been classified in a number
of ways [600]. Etiologically it could be idiopathic with no
obvious underlying cause or secondary to trauma, infection,
neoplasm, or hematologic disease including SCD, sickle trait,
other hemoglobinopathies, polycythemia, other hemolytic
disorders including enzymopathies and membranopathies
and hematologic malignancies. Clinically priapism could be
stuttering, minor, or major. Stuttering priapism is the occur-
rence of short, repetitive, and reversible painful episodes
with detumescence occurring within a few hours after the
onset of erection. This pattern has good prognosis and is
associated with normal sexual function and rarely requires
medical intervention. The prevalence of stuttering priapism
varies from about 2% of men with SCD [601] to 40–60%
of men with SCD according to other investigators [586,
596]. Minor priapism is isolated and infrequent episodes
of painful erection that last less than 4 hours and do not
require medical intervention. Major priapism, by contrast, is
a prolonged episode of painful erection lasting longer than
12 hours that often requires hospitalization with medical
and/or surgical intervention as described below. Partial or
total impotence is often associated with major episodes of
priapism. Anatomically, priapism could be bicorporal or
tricorporal. Magnetic resonance imaging (MRI) of the penis
can diﬀerentiate these two patterns. Bicorporal priapism
involves both corpora cavernosa and is common in children
with stuttering pattern. Tricorporal priapism involves both
corpora cavernosa and the corpus spongiosum and is more
common in older patients. It is painful erection that may
last several days or weeks and may be followed by complete
or partial impotence. Its prevalence varies between 6.5%
[601] and 38% [586] of men with SCD. Stroke, chronic
lung disease, chronic renal failure, and chronic leg ulcers
were observed more frequently in men who had tricorporal
priapism [601]. Priapism in adult males with SCD seems to
be a marker of severe disease and identifies patients who are
at risk for other sickle cell-related organ failures syndrome
[597, 598].
12.4. Management. Major goals of management of priapism
include pain relief and prevention of impotence. Minor
episodes of priapism and stuttering priapism usually last
less than 4 hours and are often treated at home with
analgesics, benzodiazepines, or pseudoephedrine and do not
require treatment in the emergency department (ED) or
hospital. Patients are advised to report to the emergency
department if an episode lasts longer than 4 hours. Initial
treatment in the ED should include hydration and opioid
analgesics. Catheterization of the urinary bladder may be
indicated to promote emptying. If these measures fail
to cause detumescence, penile aspiration and epinephrine
irrigation should be utilized. Mantadakis et al. [602] recom-
mend that aspiration of blood from the corpora cavernosa
followed by irrigation with dilute epinephrine should be
the initial therapy employed for patients with sickle cell
anemia and prolonged priapism. This approach may be
used by selected patients for self-management at home with
aspiration and irrigation with dilute epinephrine solution.
Simple transfusion or exchange transfusion may be tried for
patients whose priapism does not respond to the aspiration
and irrigation procedures and persists for 24 hours or
longer [589, 590, 603]. Transfusion permits the entry of
normal RBC to the engorged area and enhances oxygenation
and improves blood flow. Siegel et al. [604], however,
reported significant neurological complications in patients
with priapism who had exchange transfusion. Analysis of
their study shows that the Hb level after the blood exchange
was much higher than the patient’s baseline level. Thus
the neurological complications were most likely due to the
transfusion-induced hyperviscosity. A larger study using
blood exchange transfusion for patients with priapism and
keeping the postexchange Hb level similar to the baseline
values showed no neurological complication in any of their
patients [605]. Patients responding to transfusion therapy
usually experience detumescence within 24 to 48 hours after
the procedure. If detumescense does not occur within 24
hours following the completion of blood exchange trans-
fusion, surgical intervention should be considered. Surgical
intervention includes various shunt procedures between
the cavernosa and the spongiosum [587, 606]. Without
intervention, severe priapism results in impotence in more
than 80% of patients. The combination of transfusions and
surgery can decrease this to 25–50%. Patients who become
impotent may benefit from psychological counseling and the
insertion of prosthetic penile implants.
The role of hydroxyurea, etilefrine, leuprolide, silde-
nafil, and pseudoephedrine in preventing priapism is not
well defined at the present [598]. Anecdotally hydroxyurea
prevents or decreases the frequency of priapism in some
patients.
13. Transfusion and Iron Overload
Blood transfusion is one of the three current major
approaches for the eﬀective and promising therapeutic
approaches for SCD in general and SS in particular. The
other two include hydroxycarbamide (HCD), also known as
hydroxyurea (HU), and stem cell transplantation. Moreover
blood transfusion could be symptomatic management of
severe anemia or preventative management to prevent the
occurrence of primary and secondary strokes in children
with SS and the recurrence of acute chest syndrome in
some patients. Historically blood transfusion was second
to analgesia as a nonsurgical therapeutic approach for SS
as far back as to the 1930s and 1940s even before the
pathophysiology of the disease was well understood [607,
608]. Its utilization, however, followed a sinusoidal pattern
over the years from underutilization to overutilization and
back to what seems to be rational utilization at the present as
will be mentioned below.
Because Hb S has decreased oxygen aﬃnity and, hence,
is eﬃcient in delivering oxygen to tissues, most patients
tolerate chronic anemia with an average Hb level of 7-
8 g/dL well without the need for blood transfusion in the
steady state [609, 610]. Nevertheless patient with SCD in
general and patients with sickle cell anemia in particular are
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heavy utilizers of blood transfusion in part due to occasional
exacerbation of the anemia and in part due to coexistent
organ failure and tissue damage. Symptomatic anemia and a
decrease in Hb level to values < 5 g/dL often necessitate blood
transfusion. Jehovah’s Witnesses, however, tolerate severe
anemia with Hb level down to 2.7 g/dL [611]. Moreover,
there is a direct relation between the Hb level in the steady
state and the frequency of acute painful crises. Thus the
relatively increased Hb level associated with mild anemia
increases the blood viscosity that could precipitate acute
painful episodes [612, 613]. Other vaso-occlusive episodes
such as avascular necrosis are also more frequent in patients
with mild anemia [614, 615]. Upon deoxygenation, the
viscosity of blood containing significant amounts of Hb S
rises sharply due to the polymerization of deoxy-HbS. A
50% increase in blood viscosity increases total peripheral
resistance by 75% and reduces flow unless the pressure rises
to compensate [616].
The transfusion of blood from normal donors to patients
with sickle cell disease achieves the following two major
goals: (1) improvement of the oxygen-carrying capacity of
blood and its delivery to tissues and (2) dilution of circu-
lating sickled red cells in order to improve microvascular
perfusion. The achievement of these goals, however, is best
if Hb S is decreased to <30% and the total Hb level is
not >10 g/dL [617, 618]. Higher values of these parameters
increase blood viscosity and its associated vaso-occlusive
potential thus oﬀsetting the benefits of blood transfusion.
The availability of safe blood due to advances in donor
selection, the utilization of phenotype matching, the avail-
ability of oral iron chelators, and the reported eﬃcacy of
blood transfusion in preventing strokes and acute chest syn-
drome encouraged providers to use blood transfusion more
frequently in managing the acute and chronic complications
of SCD. Thus one study from a single institution found that
about 50% of the patients with SS admitted to the hospital
over 12-year period (1987–1998) received blood transfusion
[619]. Another study also from a single institution [620]
reported an increase in the % of transfused patients with
SCD from 17.6% in 2000-2001 to 23.9% in 2008-2009.
The indications for blood transfusion have been classified
in a number of ways. Moreover blood transfusions could
be episodic or chronic, and the transfusion method could
be simple transfusion or exchange transfusion [621–623]. In
this paper indications for blood transfusion will be classified
according to the desired objective of the transfusion. Thus
the objectives of blood transfusion could be preventa-
tive/prophylactic, abortive/curative of acute complications,
perioperative, symptomatic or for controversial objectives
(Table 1). The logistic complexities and cost associated
with blood exchange transfusion questioned whether simple
chronic transfusion obviates the need for blood exchange
transfusion. There is no easy answer to this query. The
choice depends on the nature of the complications being
treated. In acute complications such as acute chest syndrome
the goal is to bring Hb S < 30% and the total Hb to 9-
10 g/dL as soon as possible. If the patient in question has
Hb level of 5 g/dL or less simple transfusion with 3-4 unit of
RBC, to achieve the desired goal would be the appropriate
choice. If the patient in question already has Hb level of
9 g/dL with Hb S >50%, blood exchange transfusion would
be the appropriate and safe procedure to do. Moreover
chronic simple transfusion will inevitably be associated with
iron overload over a short period whereas chronic blood
exchange transfusion may delay the onset of iron overload
but is more likely to be associated with higher incidence
of alloimmunization [228] unless extensive and expensive
phenotype matching is utilized. The best approach seems
to individualize the choice of the method of transfusion
depending on the details of the clinical picture of the patient
in question.
Blood selected for transfusion to patients with SCD
should be sickle cell negative, ABO and Rh compatible,
phenotypically matched for C, E, and K antigens, leuko-
reduced and irradiated for selected patients [621]. Moreover
washed RBC may be required in patients with severe allergic
reactions due to plasma proteins. Fresh blood (blood less ≤
10 days) is often requested for blood exchange transfusion
although there is no evidence to support this request.
Because the majority of patients with SCD are Africans or
African Americans and because they receive blood given
by Caucasians, there is high incidence of alloimmunization
in transfused patients with SCD [621]. The most prevalent
alloantibodies in patients with SS include anti-C, -E, and -
K. Accordingly, the use of phenotypically matched blood,
at least for these antigens, is highly recommended [621]
and is currently routine practice in most sickle cell cen-
ters. Some blood banks implemented programs to increase
communication between the African-American community
and medical facilities to ensure the presence of blood supply
from African-American donors directed for patients with
SCD to reduce the incidence of alloimmunization to those
antigens that are prevalent in African Americans. One
concern about this practice of designated donations from
African-Americans donors to patients with SCD is that it
may increase the incidence of transfusion-related graft versus
host disease unless such blood is routinely irradiated.
Complications of blood transfusion in patients with SCD
include the transmission of infectious disease, alloimmu-
nization, hemolytic transfusion reactions (acute or delayed),
allergic reactions, febrile reactions, volume overload, and
iron overload. Multiply transfused patients before 1992,
when a screening test for hepatitis C was introduced in blood
banks, were at risk for the transmission of hepatitis C virus
(HCV). In one study [624] antibody to HCV (anti-HCV)
was detected in 21% of patients with SS. Of the patients
who received more than 10 units of blood, 30% were anti-
HCV seropositive, whereas 9% of those patients who received
<10 units were seropositive. Leukocyte-reduced RBC prepa-
rations are currently routinely used in most blood banks for
blood transfusion at large. Leukocyte-reduced components
reduce febrile reactions, decrease the chances for alloimmu-
nization to leukocyte antigens, and minimize the transmis-
sion cytomegalovirus (CMV). Patients with SCD who are
potential candidates for bone marrow or stem cell transplan-
tation should receive irradiated cellular blood components.
On a brighter note chronic transfusion therapy is
associated with a number of unintended benefits. These
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include decrease in the number of hospitalizations per year,
decrease in the frequency of painful crises, and decrease in
the frequency of acute chest syndrome [481].
Patients with SCD who receive blood transfusion chron-
ically are at risk to develop iron overload. An observational
study reported increased frequency of painful crises, organ
damage and mortality in patients with SS and iron overload
[619]. For billing purposes iron overload is coded under
transfusional hemosiderosis or hemochromatosis. The total
amount of body iron in an adult is about 3 g in women and
4 g in men. About 75% of body iron is in RBC, about one
g in the liver and smaller trace amounts in myoglobin and
certain enzymes. The human body has no mechanism to get
rid of surplus body iron.Whatever iron is introduced into the
body via infusion, blood transfusion or excessive oral intake
remains in the body. The only methods to get rid of surplus
body iron include bleeding, phlebotomy, or iron chelation
therapy. One mL of RBC contains about one mg of iron, and
the transfusion of one unit of RBC containing about 200mL
of RBC will introduce 200mg of iron into the body. By the
time 20 units of RBC are transfused, the total amount of iron
introduced into the body will be about 4 g which is double
the normal amount of total body iron. Thus the transfusion
of 20 or more units of blood, by definition, is associated with
iron overload provided there is no concomitant bleeding or
phlebotomy.
The diagnosis of iron overload entails documentation
of history of transfusion of ≥20 units of RBC in adults or
≥200mL of RBC/kg in children and confirmation of iron
overload by certain blood tests. These tests include serum
ferritin level, liver biopsy to measure the amount of iron per
g of liver dry weight and Ferriscan [625]. Other specific tests
such as MRI 2∗ or Superconducting Quantum Interference
Device (SQUID) are not available for general use. Iron
overload is best monitored by periodic determinations of
serum ferritin levels and transferrin saturation in frequently
transfused patients in the steady state [619]. Ferritin is
an acute phase reactant, and, hence, it could be falsely
elevated during painful crises, infection or inflammation.
To be a reliable indicator of iron overload, ferritin should
be determined in the steady state at least on 3 separate
occasions. If such measurements are consistent within a
reasonable range of variation, they could confirm or deny the
diagnosis of iron overload. Serum ferritin levels >1000 μg/L
and transferrin saturation >50% in the steady state are
suggestive of iron overload. To further confirm the diagnosis
of iron overload, a liver biopsy may be indicated. Hepatic
iron concentration >7mg/g liver dry weight is diagnostic of
iron overload and is an indication for iron chelation therapy
[626]. Ferriscan has been approved by the FDA, and its
advantages are that it is a noninvasive and reliable test for the
measurement of liver iron content. Its disadvantages include
cost, length of time required to do the test, and its limitation
to measure iron content in the liver only and not in other
organs.
Three iron chelators are available for the therapeutic
management of transfusional hemosiderosis [620, 627, 628].
These are deferoxamine (DFO), deferiprone (DFP), and
deferasirox (DEFRA). DFP is not approved by the FDA in
the USA and is not approved in Canada but is licensed in 61
other countries. Although DFO is an eﬀective iron chelator
that stood the test of time with over 40 years of experience,
its utilization requires tedious and lengthy subcutaneous
infusions over 10–12 hours daily for a minimum of 5 days
per week. Compliance in children has been adequate but
compliance in adults with SCD has been dismal. Oral DFP
alone or in combination with DFO has been reported to be
beneficial in general and for the management of cardiac iron
overload in particular [629–632]. Major side eﬀects of DFP
include joint pain and joint swelling in 10–30% of patients,
zinc deficiency in diabetic patients, and most seriously
transient agranulocytosis in about 0.5–1.0% of patients
usually during the first year of therapy associated with rare
fatality. DEFRA is an oral chelator approved by the FDA with
a starting daily dose of 20mg/kg with gradual escalation of
the dose if needed up to a maximum of 40mg/kg/day [627].
The most common adverse eﬀects of DEFRA included mild-
to-severe skin rashes, mild gastrointestinal disturbances,
and mild nonprogressive increase in serum creatinine and
liver enzyme levels. Agranulocytosis, arthropathy, or growth
failure due to DEFRA have not been documented to date.
Nevertheless renal failure and bleeding with occasional
fatalities have been reported. Needless to say the utilization of
any of these chelators entails frequent and careful monitoring
biweekly during the first twomonths of therapy andmonthly
thereafter. Recent review of clinical trials utilizing any of
these chelators alone or in various combinations suggests
that the use of chelation treatment in SCD to date has been
based on little eﬃcacy, and safety evidence although it is
widely used and recommended [628]. More randomized
clinical trials are needed to explore the safety, eﬃcacy, and
cost/benefit ratio evidence of iron chelation therapy in SCD.
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